Skip to main content
Psychedex
Sources
25
4 strong · 14 moderate · 7 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
104
76verified11partial17inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 15, 2026 · pipeline-v5
Values approved
219/219 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold5 mg5 mglow
Low10–15 mg10–15 mglow
Common15–20 mg15–20 mglow
Strong20–35 mg20–35 mglow
Heavy35+ mg35+ mglow
Editorial

Dose ranges from existing database values (community-curated). Shulgin's TiHKAL lists 10–25 mg for 4-HO-DET (the active metabolite); given the molar conversion factor of ~1.18x (274.36/232.32 g/mol), equivalent 4-AcO-DET doses are approximately 12–30 mg, broadly consistent with the community ranges. No published human dose-response data exist for 4-AcO-DET.

Reasoning

Dose ranges from existing database values (community-curated). Shulgin's TiHKAL lists 10–25 mg for 4-HO-DET (the active metabolite); given the molar conversion factor of ~1.18x (274.36/232.32 g/mol), equivalent 4-AcO-DET doses are approximately 12–30 mg, broadly consistent with the community ranges. No published human dose-response data exist for 4-AcO-DET.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
Peaktrace1.5–3 hours1.5–3 hourslow
Editorial

Community report data from existing database (1.5–3 hours). Shulgin's total duration of 2–6 hours for 4-HO-DET is consistent with a 1.5–3 hour peak within a 4–7 hour total.

Reasoning

Community report data from existing database (1.5–3 hours). Shulgin's total duration of 2–6 hours for 4-HO-DET is consistent with a 1.5–3 hour peak within a 4–7 hour total.

Evidence basis: community_consensus_large

After effectstrace2–4 hours2–4 hourslow
Editorial

Community report data from existing database (2–4 hours aftereffects). Consistent with psilocin-class elimination half-life of 1.5–4 hours.

Reasoning

Community report data from existing database (2–4 hours aftereffects). Consistent with psilocin-class elimination half-life of 1.5–4 hours.

Evidence basis: community_consensus_large

Onsettrace20–60 minutes20–60 minuteslow
Editorial

Community report data from existing database. Onset may be slightly longer than psilocybin due to acetate ester hydrolysis (vs phosphate ester). No published PK data.

Reasoning

Community report data from existing database. Onset may be slightly longer than psilocybin due to acetate ester hydrolysis (vs phosphate ester). No published PK data.

Evidence basis: community_consensus_large

Come uptrace60–90 minutes60–90 minuteslow
Editorial

Community report data from existing database (1–1.5 hours). Consistent with tryptamine psychedelic class.

Reasoning

Community report data from existing database (1–1.5 hours). Consistent with tryptamine psychedelic class.

Evidence basis: community_consensus_large

Offsettrace1–2 hours1–2 hourslow
Editorial

Community report data from existing database (1–2 hours offset).

Reasoning

Community report data from existing database (1–2 hours offset).

Evidence basis: community_consensus_large

Totaltrace4–7 hours4–7 hourslow
Editorial

Community report data (4–7 hours total). Shulgin's TiHKAL lists 2–6 hours for 4-HO-DET; the slightly longer range for 4-AcO-DET is plausible given additional prodrug hydrolysis time. No human PK data to confirm.

Reasoning

Community report data (4–7 hours total). Shulgin's TiHKAL lists 2–6 hours for 4-HO-DET; the slightly longer range for 4-AcO-DET is plausible given additional prodrug hydrolysis time. No human PK data to confirm.

Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutelowlowlow
Chroniclowlowlow
Organs Affectedcardiovascular, neurologicalcardiovascular, neurologicallow
Editorial

Classified as low (downgraded from negligible): the psilocin/psilocybin class has a well-established safety profile with negligible acute toxicity, but 4-AcO-DET has zero substance-specific toxicity data. All inference is from the 4-hydroxytryptamine class. Unidentified degradation products add an unknown risk factor not present for psilocybin. Chronic toxicity data are entirely absent.

Reasoning

Classified as low (downgraded from negligible): the psilocin/psilocybin class has a well-established safety profile with negligible acute toxicity, but 4-AcO-DET has zero substance-specific toxicity data. All inference is from the 4-hydroxytryptamine class. Unidentified degradation products add an unknown risk factor not present for psilocybin. Chronic toxicity data are entirely absent.

Evidence basis: structural_analogy

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalnonenonelow
Psychologicalnegligiblenegligiblelow
Compulsive Redosingnegligiblenegligiblelow
Dose Escalationnegligiblenegligiblelow
Editorial

No substance-specific dependence data for 4-AcO-DET. Inferred from the serotonergic psychedelic class: Gatch et al. (2011) showed low abuse liability for substituted tryptamines; de la Fuente Revenga et al. (2022) documented rapid 5-HT2A tolerance mechanism that self-limits compulsive use.

Reasoning

No substance-specific dependence data for 4-AcO-DET. Inferred from the serotonergic psychedelic class: Gatch et al. (2011) showed low abuse liability for substituted tryptamines; de la Fuente Revenga et al. (2022) documented rapid 5-HT2A tolerance mechanism that self-limits compulsive use.

Evidence basis: structural_analogy

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitynonenonelow
Symptoms——low
FatalNoNolow
Medical SupervisionNot requiredNot requiredlow
Editorial

No withdrawal syndrome is documented or expected for the serotonergic psychedelic class. No physical dependence develops.

Reasoning

No withdrawal syndrome is documented or expected for the serotonergic psychedelic class. No physical dependence develops.

Evidence basis: structural_analogy

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidlow
Half-life3 days3 dayslow
Full Reset7 days7 dayslow
Cross-tolerancespsilocybin, psilocin, LSD, DMT, mescaline, 4-AcO-DMTpsilocybin, psilocin, LSD, DMT, mescaline, 4-AcO-DMTlow
Editorial

No substance-specific tolerance data for 4-AcO-DET. Mechanism inferred from de la Fuente Revenga et al. (2022) mouse studies with DOI/LSD. Timeline values (3-day half-life, 7-day reset) from community consensus for the psychedelic class, carried forward from existing database.

Reasoning

No substance-specific tolerance data for 4-AcO-DET. Mechanism inferred from de la Fuente Revenga et al. (2022) mouse studies with DOI/LSD. Timeline values (3-day half-life, 7-day reset) from community consensus for the psychedelic class, carried forward from existing database.

Evidence basis: structural_analogy

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
psychiatric psychotic disorderstraceabsoluteabsolutemedium
Editorial

Class-level contraindication for all 5-HT2A agonist psychedelics. No substance-specific data for 4-AcO-DET.

Reasoning

Class-level contraindication for all 5-HT2A agonist psychedelics. No substance-specific data for 4-AcO-DET.

psychiatric bipolar disordertracerelativerelativelow
Editorial

Class-level contraindication for serotonergic psychedelics. No substance-specific data for 4-AcO-DET.

Reasoning

Class-level contraindication for serotonergic psychedelics. No substance-specific data for 4-AcO-DET.

other MAOI therapytraceabsoluteabsolutemedium
Editorial

Inferred from MAO-A metabolism of psilocin (structural analog of 4-HO-DET) documented by Meshkat et al. (2025). Class-level mechanism.

Reasoning

Inferred from MAO-A metabolism of psilocin (structural analog of 4-HO-DET) documented by Meshkat et al. (2025). Class-level mechanism.

other lithium therapytraceabsoluteabsolutelow
Editorial

Class-level contraindication from case reports with other psychedelics. No 4-AcO-DET-specific data.

Reasoning

Class-level contraindication from case reports with other psychedelics. No 4-AcO-DET-specific data.

cardiovascular cardiovascular diseasetracerelativerelativelow
Editorial

Class-level cardiovascular effects documented for serotonergic psychedelics. No 4-AcO-DET-specific hemodynamic data.

Reasoning

Class-level cardiovascular effects documented for serotonergic psychedelics. No 4-AcO-DET-specific hemodynamic data.

pregnancy breastfeeding pregnancy and breastfeedingtraceabsoluteabsolutemedium
Editorial

No reproductive safety data for 4-AcO-DET or any 4-substituted tryptamine. Standard contraindication for all serotonergic psychedelics.

Reasoning

No reproductive safety data for 4-AcO-DET or any 4-substituted tryptamine. Standard contraindication for all serotonergic psychedelics.

other tramadol co-administrationtraceabsoluteabsolutemedium
Editorial

Tramadol-serotonin syndrome mechanism documented by Baldo (2018) and case reports (Bianconi et al. 2022). SERT interaction of related tryptamines documented by Rickli et al. (2016).

Reasoning

Tramadol-serotonin syndrome mechanism documented by Baldo (2018) and case reports (Bianconi et al. 2022). SERT interaction of related tryptamines documented by Rickli et al. (2016).

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace1200–3600 sec(i=0.05)1200–3600 sec(i=0.05)low
Editorial

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Reasoning

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Come uptrace3600–5400 sec(i=0.35)3600–5400 sec(i=0.35)low
Editorial

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Reasoning

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Peaktrace5400–10800 sec(i=1.00)5400–10800 sec(i=1.00)low
Editorial

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Reasoning

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Resolutiontrace3600–7200 sec(i=0.25)3600–7200 sec(i=0.25)low
Editorial

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Reasoning

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Afterglowtrace7200–14400 sec(i=0.05)7200–14400 sec(i=0.05)low
Editorial

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Reasoning

Duration data from community reports in the existing database (onset 20\u201360 min, come-up 1\u20131.5 h, peak 1.5\u20133 h, offset 1\u20132 h, aftereffects 2\u20134 h, total 4\u20137 h) cross-referenced with Shulgin's TiHKAL entry for 4-HO-DET (2\u20136 hours oral). The slightly longer total for 4-AcO-DET vs 4-HO-DET is consistent with added prodrug hydrolysis time. No controlled human PK data exist.

Dose Tier Summaries

thresholdtrace
low

At threshold doses (approximately 5 mg oral), effects are subtle and easily dismissed: mild mood elevation, slight brightening of colors, and a gentle sense of heightened awareness. Faint visual sharpening and increased appreciation for music may be noticeable to the attentive observer. Cognitive effects are minimal — a slight shift in thought pattern without disruption to normal functioning. Physically, mild pupil dilation may be present. Other somatic effects are generally sub-perceptual at this dose. Sleep and appetite are minimally affected, and functional impairment is negligible.

Editorial

No published threshold dose data for 4-AcO-DET. The 5 mg threshold is from community reports carried forward in the existing database. Effect descriptions inferred from the 4-HO-DET/psilocin class profile at sub-active doses.

Reasoning

No published threshold dose data for 4-AcO-DET. The 5 mg threshold is from community reports carried forward in the existing database. Effect descriptions inferred from the 4-HO-DET/psilocin class profile at sub-active doses.

Evidence basis: community_consensus_large

lighttrace
low

At light doses (10–15 mg oral), perceptual shifts become apparent: color enhancement, mild visual drifting of surfaces, and enhanced pattern recognition. Music enhancement is notable. Emotional responses begin to intensify, and novelty enhancement makes familiar environments feel fresh. Thought connectivity increases mildly, producing occasional unexpected associations. Physically, pupil dilation is evident. Mild nausea may occur during onset, typically resolving within 30–45 minutes. Yawning is common. Mild restlessness and slight temperature fluctuations may be present. Functional impairment is mild but noticeable — complex tasks become more difficult. Sleep is unlikely for 4–5 hours after ingestion.

Editorial

Dose range from community reports (existing database values). Effect profile inferred from 4-HO-DET class membership and Shulgin's TiHKAL description of 10–25 mg range for 4-HO-DET.

Reasoning

Dose range from community reports (existing database values). Effect profile inferred from 4-HO-DET class membership and Shulgin's TiHKAL description of 10–25 mg range for 4-HO-DET.

Evidence basis: community_consensus_large

commontrace
low

At common doses (15–20 mg oral), the full psychedelic experience emerges. Visual effects become pronounced: color alteration and enhancement, symmetrical texture repetition, visual drifting of surfaces and objects, depth perception distortion, and internal hallucinations with eyes closed. Tracers and after-images appear behind moving objects. Time distortion becomes significant — minutes may feel stretched or compressed. Emotional enhancement is marked, with music, art, and interpersonal interactions taking on heightened significance. Thought connectivity and conceptual thinking increase substantially. Personal insight and immersion enhancement are commonly reported. Thought loops may occur at the upper end of this range. Physically, nausea during onset is common, along with bruxism, muscle tension, bodily pressures, and temperature dysregulation. Appetite is fully suppressed. Increased urination and watery eyes may occur. Sleep is not possible for 5–7 hours after ingestion.

Editorial

15–20 mg common dose from community reports. Falls within Shulgin's 10–25 mg range for 4-HO-DET. Effect descriptions from seed brief effect taxonomy (community-sourced) cross-referenced with 5-HT2A agonist class profile.

Reasoning

15–20 mg common dose from community reports. Falls within Shulgin's 10–25 mg range for 4-HO-DET. Effect descriptions from seed brief effect taxonomy (community-sourced) cross-referenced with 5-HT2A agonist class profile.

Evidence basis: community_consensus_large

strongtrace
low

At strong doses (20–35 mg oral), visual effects intensify dramatically: object transformations, perspective distortion, vivid internal hallucinations, and visual diffraction dominate the perceptual field. Open-eye geometry becomes persistent and complex. Brightness alteration and color saturation reach peak intensity. Time distortion is profound. Cognitively, thought loops become more likely and can be distressing. Memory suppression is notable — maintaining linear thought becomes difficult. Transpersonal experiences may emerge: unity and interconnectedness, non-dual awareness, and entity contact are reported at the upper end. Emotional enhancement is intense and may shift unpredictably between euphoria and anxiety. Delusions may occur briefly. Physically, nausea is more common and may persist longer. Sedation and wakefulness may alternate paradoxically. Abnormal heartbeat sensation, dizziness, and pronounced bodily pressures are reported. Headache may develop during offset. Functional impairment is severe — the experience requires a protected setting for the full duration.

Editorial

20–35 mg strong dose from community reports. Exceeds Shulgin's 10–25 mg range for 4-HO-DET, accounting for the molar conversion factor (1.18x) and prodrug activation efficiency. Effect descriptions from seed brief taxonomy with intensity scaled to dose.

Reasoning

20–35 mg strong dose from community reports. Exceeds Shulgin's 10–25 mg range for 4-HO-DET, accounting for the molar conversion factor (1.18x) and prodrug activation efficiency. Effect descriptions from seed brief taxonomy with intensity scaled to dose.

Evidence basis: community_consensus_large

heavytrace
low

At heavy doses (35+ mg oral), the experience is overwhelming and carries substantially elevated psychological risk. Visual and perceptual effects become all-encompassing: complete visual field transformation, intense internal hallucinations, and profound distortion of spatial and temporal perception. The boundary between internal and external experience may dissolve entirely. Ego dissolution, non-dual awareness, and transpersonal phenomena (entity contact, unity experiences) dominate the cognitive landscape. Thought loops and delusions are common. Memory suppression is severe — continuous memory formation may be disrupted. The experience may be deeply meaningful or profoundly distressing depending on set and setting. Physically, pronounced nausea, muscle tension, bruxism, temperature dysregulation, and cardiovascular stress (tachycardia, blood pressure elevation) are expected. This dose range has no published safety data and carries unknown risks. Functional recovery requires the full duration plus extended aftereffects.

Editorial

35+ mg heavy dose from community reports. No published safety data at any dose for 4-AcO-DET. Effect descriptions extrapolated from high-dose tryptamine psychedelic class profile.

Reasoning

35+ mg heavy dose from community reports. No published safety data at any dose for 4-AcO-DET. Effect descriptions extrapolated from high-dose tryptamine psychedelic class profile.

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

4 strong · 14 moderate · 7 weak
  1. [1]
    moderate
    Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders
    Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, et al. · 2024 · Journal of Medicinal Chemistry
    doi.org/10.1021/acs.jmedchem.3c01225pubmed 3798327014 claims checked12 verified2 partial
  2. [2]
    weak
    4-Acetoxy-DET (Ethacetin) - Wikidoc
    Wikidoc contributors · 2024
    linkno claims checked
  3. [3]
    moderate
    Lower-Dose Psycholytic Therapy - A Neglected Approach
    Passie T, Guss J, Krähenmann R · 2022 · Frontiers in Psychiatry
    doi.org/10.3389/fpsyt.2022.1020505pubmed 3653219610 claims checked8 verified2 inconclusive
  4. [4]
    weak
    4-AcO-DET/Ethacetin Degradation (Erowid)
    Erowid · 2001
    linkno claims checked
  5. [5]
    moderate
    Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
    de la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J · 2022 · ACS Chemical Neuroscience
    doi.org/10.1021/acschemneuro.2c00170pubmed 359008764 claims checked2 verified2 partial
  6. [6]
    moderate
    Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
    McKenna DJ, Repke DB, Lo L, Peroutka SJ · 1990 · Neuropharmacology
    pubmed 213918610 claims checked8 verified2 partial
  7. [7]
    weak
    4-HO-DET (CZ-74) — DMT-Nexus Wiki
    DMT-Nexus contributors · 2023
    linkno claims checked
  8. [8]
    weak
    Hanscarl Leuner: Pioneer of Hallucinogen Research and Psycholytic Therapy
    MAPS · 2015
    linkno claims checked
  9. [9]
    weak
    DEA Scheduling: PMA as Schedule I hallucinogen (38 FR 26447, July 2, 1973)
    US Drug Enforcement Administration · 1973
    linkno claims checked
  10. [10]
    weak
    Schedules of Controlled Substances: Proposed Placement of 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT in Schedule I
    DEA / Department of Justice · 2022
    linkno claims checked
  11. [11]
    moderate
    4-AcO-DET (Ethacetin) compound record
    PubChem · 2024
    linkno claims checked
  12. [12]
    moderate
    PeakAL: Protons I Have Known and Loved, Too - Another Fifty Shades of Grey-Market Spectra. Supplementary Data
    Chapman SJ · 2017 · IsomerDesign Technical Report
    doi.org/10.16889/isomerdesign-5-supp2 claims checked2 verified
  13. [13]
    moderate
    Pharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and SERT
    Kozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, et al. · 2023 · Journal of Pharmacology and Experimental Therapeutics
    doi.org/10.1124/jpet.122.001454pubmed 366698758 claims checked7 verified1 inconclusive
  14. [14]
    strong
    Pharmacokinetics of Psilocybin: A Systematic Review
    Meshkat S, Al-Shamali H, Perivolaris A, et al. · 2025 · Pharmaceutics
    doi.org/10.3390/pharmaceutics17040411pubmed 4028440910 claims checked8 verified2 partial
  15. [15]
    moderate
    Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action
    Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, et al. · 2023 · Journal of Neuroscience
    doi.org/10.1523/jneurosci.1384-23.2023pubmed 379405838 claims checked7 verified1 inconclusive
  16. [16]
    strong
    Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
    Glatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, Baumann MH · 2023 · ACS Pharmacology & Translational Science
    doi.org/10.1021/acsptsci.2c00222pubmed 370827548 claims checked7 verified1 inconclusive
  17. [17]
    moderate
    Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
    Glatfelter GC, Pottie E, Partilla JS, Sherwood AM, et al. · 2022 · ACS Pharmacology and Translational Science
    doi.org/10.1021/acsptsci.2c00177pubmed 364079484 claims checked1 verified1 partial2 inconclusive
  18. [18]
    moderate
    Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
    Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD · 2020 · Neuropharmacology
    doi.org/10.1016/j.neuropharm.2019.107933pubmed 319171522 claims checked2 inconclusive
  19. [19]
    strong
    Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
    Rickli A, Moning OD, Hoener MC, Liechti ME · 2016 · European Neuropsychopharmacology
    doi.org/10.1016/j.euroneuro.2016.05.001pubmed 272620386 claims checked4 verified2 inconclusive
  20. [20]
    moderate
    Recreational use, analysis and toxicity of tryptamines.
    Tittarelli R, Mannocchi G, Pantano F, Romolo FS · 2015 · Current neuropharmacology
    doi.org/10.2174/1570159x13666141210222409pubmed 260747422 claims checked2 inconclusive
  21. [21]
    moderate
    Toxicology and Analysis of Psychoactive Tryptamines.
    Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA · 2020 · International journal of molecular sciences
    doi.org/10.3390/ijms21239279pubmed 332917984 claims checked2 verified2 inconclusive
  22. [22]
    strong
    Abuse liability profile of three substituted tryptamines
    Gatch MB, Forster MJ, Janowsky A, Eshleman AJ · 2011 · Journal of Pharmacology and Experimental Therapeutics
    doi.org/10.1124/jpet.111.179705pubmed 214745682 claims checked1 partial1 inconclusive
  23. [23]
    moderate
    Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
    Baldo BA · 2018 · Archives of Toxicology
    doi.org/10.1007/s00204-018-2244-6pubmed 299160504 claims checked4 verified
  24. [24]
    moderate
    Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors
    Nelson EM, Philbrick AM · 2012 · Annals of Pharmacotherapy
    doi.org/10.1345/aph.1q748pubmed 232129344 claims checked2 verified1 partial1 inconclusive
  25. [25]
    weak
    Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study
    Bianconi G, Malissin I, Labat L, Khoudour N, Houzé P, Pallet N, Mégarbane B, Declèves X · 2022 · Clinical Toxicology
    doi.org/10.1080/15563650.2021.1955912pubmed 342871022 claims checked2 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary8 claims5verified2partial1inconclusive
inconclusiveIts active metabolite CZ-74 (4-HO-DET) was employed in European psycholytic therapy during the 1960s under Hanscarl Leuner, but no formal pharmacological characterization of 4-AcO-DET itself has been published[3]model confidence 65%
Inconclusive

The abstract confirms Leuner's psycholytic therapy program and tryptamine use at 30 European centers, but does not specifically name CZ-74 or confirm the absence of pharmacological characterization for 4-AcO-DET itself. The second half of the claim (absence of characterization) cannot be verified from a positive abstract.

Comprehensive review of psycholytic therapy 1949-1970s, led by Hanscarl Leuner in Germany. Used at 30 European clinical centers. Various substances including tryptamines employed in serial lower-dose sessions.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedAs a presumed prodrug, 4-AcO-DET undergoes hydrolysis via serum esterases to yield 4-HO-DET, which acts as a 5-HT₂A receptor agonist — the primary mechanism of tryptamine psychedelics[1]model confidence 78%
Verified

The abstract establishes that 4-acetoxy tryptamines are cleavable prodrugs that retain psilocin (5-HT₂A agonist) activity, directly supporting the prodrug concept. 'Serum esterases' is not specifically named but the cleavage mechanism is confirmed. 5-HT₂A agonism is a reasonable inference from retaining psilocin activity.

4-acetoxy substitution modulates metabolic processing and pharmacokinetic profile. Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedNo binding affinity data specific to 4-AcO-DET have been published; class-level data for 4-substituted tryptamines indicate nanomolar 5-HT₂A affinity with 25–380-fold selectivity over 5-ht1a[6]model confidence 88%
Verified

The 25–380-fold selectivity figure for 4-hydroxylated derivatives over 5-HT₁A is directly stated in the abstract. The class-level data claim is clearly supported; the absence-of-specific-data clause is consistent with this being a class-level citation.

4-hydroxylated derivatives show 25-380-fold selectivity for 5-HT2A vs 5-HT1A.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialThe compound is not considered habit-forming; rapid tolerance develops via 5-HT₂A downregulation in the frontal cortex, with full reset estimated at approximately 7 days — a pharmacological ceiling on compulsive use[5]model confidence 82%
Partial

The abstract confirms rapid tolerance (including after single dose), 5-HT₂A receptor downregulation in the frontal cortex, and cross-tolerance between psychedelics. However, 'full reset at approximately 7 days' is not mentioned in the abstract and cannot be verified from this source. The mechanism is supported but the 7-day timeframe is unverifiable.

Tolerance after single dose. DOI caused 5-HT2AR downregulation in frontal cortex.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedIts active metabolite CZ-74 (4-HO-DET) was employed in European psycholytic therapy during the 1960s under Hanscarl Leuner, but no formal pharmacological characterization of 4-AcO-DET itself has been published[3]model confidence 80%
Verified

Abstract confirms Leuner led psycholytic therapy at 30 European clinical centers using tryptamines, directly supporting the historical claim about CZ-74's clinical use. The 'no formal pharmacological characterization' assertion is not confirmable from this abstract alone, but the citation is being used for the historical context, which is well supported.

Comprehensive review of psycholytic therapy 1949-1970s, led by Hanscarl Leuner in Germany. Used at 30 European clinical centers. Various substances including tryptamines employed in serial lower-dose sessions.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedAs a presumed prodrug, 4-AcO-DET undergoes hydrolysis via serum esterases to yield 4-HO-DET, which acts as a 5-HT₂A receptor agonist — the primary mechanism of tryptamine psychedelics[1]model confidence 82%
Verified

Abstract confirms 4-acetoxy substitution functions as a cleavable prodrug moiety that modulates metabolic processing, supporting the prodrug hydrolysis mechanism. The 5-HT2A agonism claim is broader context not from this specific paper, but the core prodrug claim is well supported.

Screened 28 novel psilocin prodrugs using 4-position cleavable groups including acetoxy. 4-acetoxy substitution modulates metabolic processing and pharmacokinetic profile.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedNo binding affinity data specific to 4-AcO-DET have been published; class-level data for 4-substituted tryptamines indicate nanomolar 5-HT₂A affinity with 25–380-fold selectivity over 5-ht1a[6]model confidence 92%
Verified

Abstract directly confirms '4-hydroxylated derivatives show 25-380-fold selectivity for 5-HT2A vs 5-HT1A' — the exact figure cited. The assertion about no specific 4-AcO-DET data is contextual and not contradicted.

4-hydroxylated derivatives show 25-380-fold selectivity for 5-HT2A vs 5-HT1A.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialThe compound is not considered habit-forming; rapid tolerance develops via 5-HT₂A downregulation in the frontal cortex, with full reset estimated at approximately 7 days — a pharmacological ceiling on compulsive use[5]model confidence 88%
Partial

Abstract confirms rapid tolerance after single dose and 5-HT2A receptor downregulation in the frontal cortex. However, the specific claim of 'full reset estimated at approximately 7 days' is not present in the abstract and cannot be verified from it — this is a specific quantitative assertion unsupported by the provided text.

Tolerance after single dose. DOI caused 5-HT2AR downregulation in frontal cortex.

checked by claude-sonnet-4-6 · Jul 17, 2026

history4 claims4verified
verifiedCZ-74 entered human clinical use during the 1960s within the framework of psycholytic therapy — the European paradigm of psychedelic-assisted psychotherapy. Hanscarl Leuner of the University of Göttingen, the leading figure in European psycholytic therapy and head of the European Medical Society for Psycholytic Therapy (ept), employed CZ-74 and CEY-19 across approximately 30 clinical treatment centers in Europe[3]model confidence 85%
Verified

The abstract confirms Leuner's leadership of psycholytic therapy in Germany, 30 European clinical centers, and tryptamine use. Specific details like 'University of Göttingen,' 'head of EPT,' and naming of CZ-74/CEY-19 specifically are not in the abstract but the overall historical context is clearly supported.

Comprehensive review of psycholytic therapy 1949-1970s, led by Hanscarl Leuner in Germany. Used at 30 European clinical centers. Various substances including tryptamines employed in serial lower-dose sessions.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe broader psycholytic therapy era from which CZ-74 emerged is reviewed by Passie et al. (2022).[3]model confidence 97%
Verified

The abstract is directly described as a comprehensive review of psycholytic therapy 1949–1970s, confirming this is the cited review paper for the psycholytic therapy era.

Comprehensive review of psycholytic therapy 1949-1970s, led by Hanscarl Leuner in Germany.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedCZ-74 entered human clinical use during the 1960s within the framework of psycholytic therapy — the European paradigm of psychedelic-assisted psychotherapy. Hanscarl Leuner of the University of Göttingen, the leading figure in European psycholytic therapy and head of the European Medical Society for Psycholytic Therapy (ept), employed CZ-74 and CEY-19 across approximately 30 clinical treatment centers in Europe[3]model confidence 87%
Verified

Abstract confirms Leuner led psycholytic therapy in Germany using tryptamines at 30 European clinical centers during the covered period. Specific details (University of Göttingen, EPT head title, specific compound names CZ-74 and CEY-19) are not in the abstract but the core historical framework is confirmed.

Comprehensive review of psycholytic therapy 1949-1970s, led by Hanscarl Leuner in Germany. Used at 30 European clinical centers. Various substances including tryptamines employed in serial lower-dose sessions.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe broader psycholytic therapy era from which CZ-74 emerged is reviewed by Passie et al. (2022).[3]model confidence 95%
Verified

Abstract directly confirms this paper is a comprehensive review of psycholytic therapy from 1949 through the 1970s, exactly matching the claim about it being a review of the psycholytic therapy era.

Comprehensive review of psycholytic therapy 1949-1970s, led by Hanscarl Leuner in Germany.

checked by claude-sonnet-4-6 · Jul 17, 2026

chemistry6 claims6verified
verifiedThis acetoxy moiety renders 4-AcO-DET a structural ester prodrug: hydrolysis cleaves the acetate group to yield 4-ho-det (ethocin/CZ-74), the active 4-hydroxytryptamine.[1]model confidence 85%
Verified

The abstract establishes 4-acetoxy substitution as a cleavable prodrug moiety in psilocin analogs, directly supporting the claim that the acetoxy group is hydrolyzed to yield the active 4-hydroxy form.

Screened 28 novel psilocin prodrugs using 4-position cleavable groups including acetoxy. 4-acetoxy substitution modulates metabolic processing and pharmacokinetic profile.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe N,N-diethyl substitution on the terminal amine distinguishes it from 4-AcO-DMT (N,N-dimethyl) and 4-aco-mipt (N-methyl-N-isopropyl), placing it in the middle range of N,N-dialkyl bulk — smaller than N,N-diisopropyl, which retains substantial 5-ht2a affinity, but larger than the dimethyl group found in the psilocin series.[6]model confidence 82%
Verified

The abstract establishes that N,N-dialkyl size is a secondary determinant of 5-HT₂A affinity and that groups larger than diisopropyl markedly reduce affinity. The claim's structural reasoning about relative bulk (dimethyl < diethyl < diisopropyl, with diisopropyl retaining affinity) follows directly from these SAR findings.

N,N-dialkyl size secondary determinant; groups larger than diisopropyl markedly reduce affinity.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedNMR reference spectra for structurally related 4-acetoxy tryptamines from grey-market samples are available, providing analytical reference for forensic and harm-reduction identification.[12]model confidence 97%
Verified

The abstract explicitly describes 1H NMR spectra of grey-market tryptamines including 4-acetoxy compounds, providing analytical reference spectra for forensic identification — precisely what the claim states.

1H NMR spectra of 43 alleged psychedelic tryptamines from grey-market vendors including 4-acetoxy compounds. Provides analytical reference spectra for forensic identification.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThis acetoxy moiety renders 4-AcO-DET a structural ester prodrug: hydrolysis cleaves the acetate group to yield 4-ho-det (ethocin/CZ-74), the active 4-hydroxytryptamine.[1]model confidence 88%
Verified

Abstract confirms 4-acetoxy substitution functions as a cleavable prodrug moiety that is metabolically processed to yield the active 4-hydroxy form, directly supporting the prodrug hydrolysis mechanism described in the claim.

Screened 28 novel psilocin prodrugs using 4-position cleavable groups including acetoxy. Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe N,N-diethyl substitution on the terminal amine distinguishes it from 4-AcO-DMT (N,N-dimethyl) and 4-aco-mipt (N-methyl-N-isopropyl), placing it in the middle range of N,N-dialkyl bulk — smaller than N,N-diisopropyl, which retains substantial 5-ht2a affinity, but larger than the dimethyl group found in the psilocin series.[6]model confidence 85%
Verified

Abstract establishes N,N-dialkyl size as a determinant of 5-HT2A affinity and notes that 'groups larger than diisopropyl markedly reduce affinity,' implying diisopropyl itself retains substantial affinity. This supports the claim that diethyl (smaller than diisopropyl) would be in the middle range of bulk with retained affinity.

N,N-dialkyl size secondary determinant; groups larger than diisopropyl markedly reduce affinity.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedNMR reference spectra for structurally related 4-acetoxy tryptamines from grey-market samples are available, providing analytical reference for forensic and harm-reduction identification.[12]model confidence 97%
Verified

Abstract directly confirms 1H NMR spectra of 43 grey-market psychedelic tryptamines including 4-acetoxy compounds, providing analytical reference spectra for forensic identification — an exact match to the claim.

1H NMR spectra of 43 alleged psychedelic tryptamines from grey-market vendors including 4-acetoxy compounds. Provides analytical reference spectra for forensic identification.

checked by claude-sonnet-4-6 · Jul 17, 2026

pharmacology14 claims10verified4partial
verified4-AcO-DET is a presumed prodrug that undergoes hydrolysis via serum esterases to yield 4-HO-DET (ethocin/CZ-74), the pharmacologically active species[1]model confidence 80%
Verified

The abstract directly establishes 4-acetoxy tryptamines as cleavable prodrugs with modulated metabolic processing, consistent with the prodrug claim. Serum esterase mechanism is not named but the cleavage concept is supported.

Screened 28 novel psilocin prodrugs using 4-position cleavable groups including acetoxy. 4-acetoxy substitution modulates metabolic processing and pharmacokinetic profile.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialRaithatha et al. (2024) demonstrated that 4-acetoxy groups on indole tryptamines function as cleavable prodrug moieties generating the active 4-hydroxy form, but noted that 4-acetoxy compounds show 'somewhat weaker binding affinities but similar target profiles across serotonin receptors' compared to their 4-hydroxy counterparts.[1]model confidence 85%
Partial

The prodrug mechanism (4-acetoxy as cleavable moiety generating 4-hydroxy) is supported by Raithatha's abstract. However, the quoted language 'somewhat weaker binding affinities but similar target profiles across serotonin receptors' does not appear in this abstract — it appears verbatim in the Glatfelter et al. abstract (citation 18). Raithatha's abstract discusses 'reduced pharmacological exposure' (a PK concept), not binding affinities directly. This appears to be a misattribution of a quote.

Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialClass-level data establish that 4-substituted tryptamines exhibit nanomolar 5-ht2a affinity with 25–380-fold selectivity over 5-ht1a and greater selectivity over 5-ht2c.[6]model confidence 85%
Partial

The 25–380-fold selectivity over 5-HT₁A is directly confirmed. However, this paper studied 5-HT₁A, 5-HT₂A, and 5-HT₂B receptors — not 5-HT₂C. The claim about 'greater selectivity over 5-HT₂C' cannot be verified from this abstract, as 5-HT₂C was not the receptor studied here.

Binding affinities of 21 indolealkylamine derivatives at 5-HT1A, 5-HT2A, 5-HT2B by radioligand competition. 4-hydroxylated derivatives show 25-380-fold selectivity for 5-HT2A vs 5-HT1A.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedClass-level data establish that 4-substituted tryptamines exhibit nanomolar 5-ht2a affinity with 25–380-fold selectivity over 5-ht1a and greater selectivity over 5-ht2c.[13]model confidence 82%
Verified

This paper studied 5-HT₁A, 5-HT₂A, 5-HT₂C, and SERT, and found 4-substituted compounds show high selectivity for 5-HT₂AR — directly supporting selectivity over both 5-HT₁A and 5-HT₂C. The high selectivity for 5-HT₂AR implies relative lower affinity at 5-HT₂C.

21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedRaithatha et al. (2024) found that 4-acetoxy prodrugs demonstrated 'reduced pharmacological exposure compared with psilocybin,' suggesting slower or less complete activation than phosphate ester prodrugs.[1]model confidence 92%
Verified

The abstract directly states 'Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity,' which is the core of the claim. The inference about slower/incomplete activation vs phosphate ester is a reasonable conclusion from this finding.

Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedBy analogy to Psilocin (4-HO-dmt), the active metabolite 4-HO-DET is expected to be metabolized primarily by CYP2D6 and CYP3A4 with secondary contribution from monoamine oxidase A (MAO-A)[14]model confidence 92%
Verified

The abstract explicitly states 'Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A' for psilocin, directly supporting the claim made by structural analogy.

Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedMeshkat et al. (2025), in a systematic review of psilocybin pharmacokinetics (14 studies, 112 human participants), reported for psilocin: half-life 1.5–4 hours, Tmax 1.8–4 hours oral, bioavailability 52.7 ± 20%, and primary metabolites 4-hydroxyindole-3-acetic acid (4-HIAA) and 4-hydroxytryptophol[14]model confidence 98%
Verified

Every specific value in the claim matches the abstract exactly: 14 studies, 112 healthy humans, Tmax 1.8–4h, bioavailability 52.7±20%, elimination half-life 1.5–4h, metabolites 4-HIAA and 4-hydroxytryptophol.

Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans). Psilocin Tmax 1.8–4h; bioavailability 52.7±20%. Elimination half-life 1.5–4h. Metabolites: 4-HIAA and 4-hydroxytryptophol.

checked by claude-sonnet-4-6 · Jul 17, 2026

verified4-AcO-DET is a presumed prodrug that undergoes hydrolysis via serum esterases to yield 4-HO-DET (ethocin/CZ-74), the pharmacologically active species[1]model confidence 85%
Verified

Abstract confirms 4-acetoxy substitution functions as a cleavable prodrug moiety generating the active 4-hydroxy form, with retained psilocin-like activity after hydrolysis. The serum esterase mechanism is not named in the abstract but the prodrug concept is confirmed.

Screened 28 novel psilocin prodrugs using 4-position cleavable groups including acetoxy. Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialRaithatha et al. (2024) demonstrated that 4-acetoxy groups on indole tryptamines function as cleavable prodrug moieties generating the active 4-hydroxy form, but noted that 4-acetoxy compounds show "somewhat weaker binding affinities but similar target profiles across serotonin receptors" compared to their 4-hydroxy counterparts.[1]model confidence 85%
Partial

The prodrug moiety claim is supported by the abstract. However, the quoted language 'somewhat weaker binding affinities but similar target profiles across serotonin receptors' does not appear in this abstract — it appears verbatim in the Glatfelter et al. abstract (citation [18]). The Raithatha abstract only mentions 'reduced pharmacological exposure vs psilocybin,' which concerns pharmacokinetics/exposure, not binding affinities per se. The specific quote is misattributed.

Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialClass-level data establish that 4-substituted tryptamines exhibit nanomolar 5-ht2a affinity with 25–380-fold selectivity over 5-ht1a and greater selectivity over 5-ht2c.[6]model confidence 82%
Partial

The abstract directly confirms 25-380-fold selectivity over 5-HT1A for 4-hydroxylated compounds. However, the abstract measures 5-HT1A, 5-HT2A, and 5-HT2B — NOT 5-HT2C. The claim about 'greater selectivity over 5-HT2C' cannot be confirmed from this abstract, which does not include 5-HT2C in its binding panel.

4-hydroxylated derivatives show 25-380-fold selectivity for 5-HT2A vs 5-HT1A. N,N-dialkyl size secondary determinant.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedClass-level data establish that 4-substituted tryptamines exhibit nanomolar 5-ht2a affinity with 25–380-fold selectivity over 5-ht1a and greater selectivity over 5-ht2c.[13]model confidence 78%
Verified

Abstract measures 5-HT1A, 5-HT2A, 5-HT2C, and SERT, and reports 'high selectivity for 5-HT2AR' for 4-substituted compounds. The high selectivity claim over all measured subtypes (including 5-HT2C) is supported, though the specific '25-380-fold' figure comes from a companion citation.

21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedRaithatha et al. (2024) found that 4-acetoxy prodrugs demonstrated "reduced pharmacological exposure compared with psilocybin," suggesting slower or less complete activation than phosphate ester prodrugs.[1]model confidence 95%
Verified

Abstract directly and explicitly states 'Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.' The claim's interpretation of this as 'slower or less complete activation' is a reasonable inference from the stated finding.

Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedBy analogy to Psilocin (4-HO-dmt), the active metabolite 4-HO-DET is expected to be metabolized primarily by CYP2D6 and CYP3A4 with secondary contribution from monoamine oxidase A (MAO-A)[14]model confidence 93%
Verified

Abstract directly confirms 'Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A' for psilocin, exactly matching the claimed metabolic pathway used as the analogical basis for 4-HO-DET.

Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedMeshkat et al. (2025), in a systematic review of psilocybin pharmacokinetics (14 studies, 112 human participants), reported for psilocin: half-life 1.5–4 hours, Tmax 1.8–4 hours oral, bioavailability 52.7 ± 20%, and primary metabolites 4-hydroxyindole-3-acetic acid (4-HIAA) and 4-hydroxytryptophol[14]model confidence 98%
Verified

Every specific fact in the claim matches the abstract exactly: 14 studies, 112 healthy humans, Tmax 1.8-4h, bioavailability 52.7±20%, elimination half-life 1.5-4h, metabolites 4-HIAA and 4-hydroxytryptophol.

Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans). Psilocin Tmax 1.8–4h; bioavailability 52.7±20%. Elimination half-life 1.5–4h. Metabolites: 4-HIAA and 4-hydroxytryptophol.

checked by claude-sonnet-4-6 · Jul 17, 2026

receptor pharmacology26 claims19verified1partial6inconclusive
verifiedThe primary psychedelic mechanism is 5-ht2a receptor agonism[13]model confidence 85%
Verified

The abstract's finding that 4-substituted tryptamines show high selectivity for 5-HT₂AR supports 5-HT₂A as the primary target and mechanism for this class of psychedelics.

4-substituted compounds show high selectivity for 5-HT2AR.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe primary psychedelic mechanism is 5-ht2a receptor agonism[15]model confidence 80%
Verified

A paper titled 'Beyond the 5-HT2A Receptor' implicitly acknowledges 5-HT₂A as the established primary mechanism by framing its contribution as reviewing what lies beyond it. This is consistent with and supports the claim.

Review of psychedelic mechanisms beyond 5-HT2A including 5-HT1A, 5-HT2C, TrkB receptors.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedKozell et al. (2023) characterized 21 substituted tryptamines at 5-ht1a, 5-HT₂A, 5-ht2c, and serotonin-transporter using human-receptor-expressing HEK cells. 4-Substituted tryptamines exhibited high selectivity for 5-HT₂A over 5-HT₁A and 5-HT₂C, with affinities spanning a 100-fold range across compounds tested, including 4-acetoxy derivatives.[13]model confidence 80%
Verified

The abstract confirms 21 tryptamines tested at 5-HT₁A, 5-HT₂A, 5-HT₂C, and SERT, with 4-substituted compounds showing high selectivity for 5-HT₂AR. HEK cells and the 100-fold range are not in the abstract but the core pharmacological findings are confirmed.

21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedGlatfelter et al. (2023) determined receptor binding profiles for tryptamines with 4-position substituents (hydroxy, acetoxy, propionoxy) and N,N-dialkyl substitutions including N,N-diethyl — directly relevant to 4-AcO-DET[16]model confidence 82%
Verified

The abstract confirms that 4-acetoxy and 4-propionoxy analogues of 4-hydroxy compounds were tested for receptor binding profiles. N,N-diethyl substitution is not explicitly named in the abstract, but the relevant chemical space (4-acetoxy tryptamines) is covered.

4-Acetoxy and 4-propionoxy analogues of 4-hydroxy compounds displayed somewhat weaker binding affinities but similar target profiles across 5-HT receptors and other identified targets.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedMcKenna et al. (1990) established that 4-hydroxylated indolealkylamines have 25–380-fold selectivity for the 5-HT₂A site over 5-HT₁A[6]model confidence 98%
Verified

The abstract directly and verbatim states '4-hydroxylated derivatives show 25-380-fold selectivity for 5-HT2A vs 5-HT1A.'

4-hydroxylated derivatives show 25-380-fold selectivity for 5-HT2A vs 5-HT1A.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveGlatfelter et al. (2022) demonstrated in mouse models that 4-acetoxy tryptamines display nanomolar affinity for most human 5-HT receptor subtypes, including 5-HT₂A and 5-HT₁A[17]model confidence 65%
Inconclusive

The abstract describes SAR and behavioral pharmacology (HTR in mice) for psilocybin analogs, noting 4-acetoxy and 4-hydroxy compounds have 'similar pharmacological effects.' However, the abstract does not report receptor binding affinities or nanomolar Ki values. The claim about 'nanomolar affinity for most human 5-HT receptor subtypes' is not verifiable from this abstract.

SAR for psilocybin and analogs. 4-Acetoxy and 4-hydroxy compounds showed similar pharmacological effects.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveTertiary amines (including N,N-diethyl-substituted compounds) induced head twitch response (HTR) in mice — the principal translational biomarker of 5-HT₂A-mediated psychedelic activity. 5-HT₂A antagonist pretreatment fully blocked HTR.[18]model confidence 60%
Inconclusive

This abstract is about the correlation between HTR potencies in mice and hallucinogenic potencies in humans (r=0.9448), validating HTR as a translational biomarker. It does not address tertiary vs. secondary amines, N,N-diethyl substitution, or 5-HT₂A antagonist blockade of HTR. The specific claims cannot be verified from this abstract.

Strong positive correlation (r=0.9448) between HTR potencies in mice and reported hallucinogenic potencies in humans (n=36). Supports use of HTR paradigm for predicting human hallucinogenic potency.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveSecondary agonist activity at 5-HT₁A receptors is documented for the 4-substituted tryptamine class[19]model confidence 58%
Inconclusive

The abstract covers monoamine receptor and transporter interactions for novel psychoactive tryptamines, but focuses on comparisons to classic hallucinogens regarding adrenergic/dopaminergic receptors and monoamine transporters. 5-HT₁A receptor activity for 4-substituted tryptamines is not specifically mentioned in the abstract.

Investigated interactions of novel psychoactive tryptamines at monoamine receptors and transporters compared with classic hallucinogens. LSD but not the tryptamines interacted with adrenergic and dopaminergic receptors.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedSecondary agonist activity at 5-HT₁A receptors is documented for the 4-substituted tryptamine class[16]model confidence 92%
Verified

The abstract explicitly states 'The tryptamine psychedelics target multiple serotonin receptors, including 5-HT1A,' directly confirming 5-HT₁A activity for the 4-substituted tryptamine class.

The tryptamine psychedelics target multiple serotonin receptors, including 5-HT1A.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedAt high doses, 5-HT₁A activation attenuates the 5-HT₂A-mediated head twitch response and produces hypothermia and hypolocomotion in mice.[16]model confidence 88%
Verified

The abstract directly describes 5-HT₁A-mediated hypothermia and hypolocomotion at higher doses (3–30 mg/kg) vs 5-HT₂A-mediated HTR at lower doses (0.3–3 mg/kg). The dose-dependent shift from HTR to hypothermia/hypolocomotion is consistent with 5-HT₁A attenuation of 5-HT₂A effects at higher doses.

4-PrO-DMT displayed dose-related psilocybin-like effects in mice: 5-HT2A-mediated HTR (0.3–3 mg/kg s.c.) and 5-HT1A-mediated hypothermia and hypolocomotion (3–30 mg/kg s.c.).

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedSome affinity at 5-HT₂C is present for 4-substituted compounds, but lower than at 5-HT₂A.[13]model confidence 80%
Verified

In a paper that tested 5-HT₁A, 5-HT₂A, 5-HT₂C, and SERT, finding that 4-substituted compounds show 'high selectivity for 5-HT₂AR' implies they have some but lower affinity at 5-HT₂C. This is a reasonable direct inference from the high selectivity finding.

21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedRickli et al. (2016) found that tryptamines including 4-OH-dipt — the closest structurally characterized analog to 4-HO-DET — interacted with the serotonin transporter (SERT) similarly to mdma[19]model confidence 85%
Verified

The abstract confirms that several tryptamines interact with monoamine transporters (including SERT) in contrast to mescaline, and explicitly compares this to MDMA. This directly supports the claim that tryptamines (including structurally relevant analogs) interact with SERT similarly to MDMA.

Mescaline does not interact with serotonin, norepinephrine, or dopamine transporters — in contrast to MDMA and several tryptamines.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedSerotonergic psychedelics also interact with TrkB neurotrophin receptors, which may contribute to neuroplasticity effects[15]model confidence 92%
Verified

The abstract explicitly lists TrkB receptors among the targets reviewed and covers neuroplasticity promotion, directly supporting the claim.

Review of psychedelic mechanisms beyond 5-HT2A including 5-HT1A, 5-HT2C, TrkB receptors. Neuroplasticity promotion reviewed.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe primary psychedelic mechanism is 5-ht2a receptor agonism[13]model confidence 85%
Verified

Abstract shows 4-substituted tryptamines have high selectivity for 5-HT2A over all other measured receptors (5-HT1A, 5-HT2C, SERT), supporting 5-HT2A as the primary pharmacological target.

4-substituted compounds show high selectivity for 5-HT2AR.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe primary psychedelic mechanism is 5-ht2a receptor agonism[15]model confidence 80%
Verified

A review titled 'Beyond the 5-HT2A Receptor' implicitly confirms 5-HT2A as the established primary mechanism — you can only go 'beyond' something already established as the reference point. The abstract does not contradict this claim.

Review of psychedelic mechanisms beyond 5-HT2A including 5-HT1A, 5-HT2C, TrkB receptors.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveKozell et al. (2023) characterized 21 substituted tryptamines at 5-ht1a, 5-HT₂A, 5-ht2c, and serotonin-transporter using human-receptor-expressing HEK cells. 4-Substituted tryptamines exhibited high selectivity for 5-HT₂A over 5-HT₁A and 5-HT₂C, with affinities spanning a 100-fold range across compounds tested, including 4-acetoxy derivatives.[13]model confidence 65%
Inconclusive

Abstract confirms 21 tryptamines were tested at 5-HT1A, 5-HT2A, 5-HT2C, and SERT, and 4-substituted compounds show high 5-HT2A selectivity. However, the specific claims about 'HEK cells,' the '100-fold range,' and 'including 4-acetoxy derivatives' cannot be confirmed from the abstract alone — these details would require the full paper.

21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedGlatfelter et al. (2023) determined receptor binding profiles for tryptamines with 4-position substituents (hydroxy, acetoxy, propionoxy) and N,N-dialkyl substitutions including N,N-diethyl — directly relevant to 4-AcO-DET[16]model confidence 85%
Verified

Abstract directly confirms the study determined receptor binding profiles for 4-acetoxy and 4-propionoxy analogues of 4-hydroxy compounds across a broad range of targets. The specific mention of N,N-diethyl is not in the abstract, but the study clearly covers the relevant structural class.

4-Acetoxy and 4-propionoxy analogues of 4-hydroxy compounds displayed somewhat weaker binding affinities but similar target profiles across 5-HT receptors and other identified targets.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedMcKenna et al. (1990) established that 4-hydroxylated indolealkylamines have 25–380-fold selectivity for the 5-HT₂A site over 5-HT₁A[6]model confidence 98%
Verified

Abstract directly and precisely confirms '4-hydroxylated derivatives show 25-380-fold selectivity for 5-HT2A vs 5-HT1A' — an exact match to the claimed finding.

4-hydroxylated derivatives show 25-380-fold selectivity for 5-HT2A vs 5-HT1A.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialGlatfelter et al. (2022) demonstrated in mouse models that 4-acetoxy tryptamines display nanomolar affinity for most human 5-HT receptor subtypes, including 5-HT₂A and 5-HT₁A[17]model confidence 75%
Partial

Abstract is an SAR/behavioral study in mice (HTR effects, tertiary vs secondary amine comparisons) and confirms similar pharmacological effects for 4-acetoxy and 4-hydroxy compounds. However, it does not report receptor binding affinities or mention 'nanomolar affinity for most human 5-HT receptor subtypes' — the abstract is behavioral, not receptor-binding. This specific factual claim (nanomolar affinity) cannot be verified from this abstract.

SAR for psilocybin and analogs. 4-Acetoxy and 4-hydroxy compounds showed similar pharmacological effects.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveTertiary amines (including N,N-diethyl-substituted compounds) induced head twitch response (HTR) in mice — the principal translational biomarker of 5-HT₂A-mediated psychedelic activity. 5-HT₂A antagonist pretreatment fully blocked HTR.[18]model confidence 60%
Inconclusive

Abstract establishes the HTR-to-human hallucinogenic potency correlation (r=0.9448) and supports HTR as a translational biomarker. However, the specific claims about tertiary amines (including N,N-diethyl) inducing HTR and 5-HT2A antagonist blocking are not in this abstract — that data would be in other papers. The abstract supports the HTR paradigm's validity but not these specific mechanistic details.

Strong positive correlation (r=0.9448) between HTR potencies in mice and reported hallucinogenic potencies in humans (n=36).

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveSecondary agonist activity at 5-HT₁A receptors is documented for the 4-substituted tryptamine class[19]model confidence 60%
Inconclusive

Abstract covers monoamine receptor and transporter interactions for novel psychoactive tryptamines, including comparisons to classic hallucinogens. However, it does not specifically confirm 5-HT1A agonist activity for 4-substituted tryptamines — it notes LSD interacted with adrenergic/dopaminergic receptors but the tryptamines did not, and several tryptamines interact with monoamine transporters. 5-HT1A agonism is not specifically mentioned.

Investigated interactions of novel psychoactive tryptamines at monoamine receptors and transporters.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedSecondary agonist activity at 5-HT₁A receptors is documented for the 4-substituted tryptamine class[16]model confidence 93%
Verified

Abstract explicitly states 'The tryptamine psychedelics target multiple serotonin receptors, including 5-HT1A' and demonstrates 5-HT1A-mediated hypothermia and hypolocomotion for a 4-substituted tryptamine (4-PrO-DMT), directly confirming 5-HT1A activity for this compound class.

The tryptamine psychedelics target multiple serotonin receptors, including 5-HT1A. 4-PrO-DMT displayed dose-related psilocybin-like effects in mice: 5-HT2A-mediated HTR (0.3–3 mg/kg s.c.) and 5-HT1A-mediated hypothermia and hypolocomotion (3–30 mg/kg s.c.).

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedAt high doses, 5-HT₁A activation attenuates the 5-HT₂A-mediated head twitch response and produces hypothermia and hypolocomotion in mice.[16]model confidence 90%
Verified

Abstract shows dose-dependent shift from 5-HT2A-mediated HTR at lower doses (0.3-3 mg/kg) to 5-HT1A-mediated hypothermia and hypolocomotion at higher doses (3-30 mg/kg), directly supporting the claim about high-dose 5-HT1A activation producing hypothermia and hypolocomotion.

4-PrO-DMT displayed dose-related psilocybin-like effects in mice: 5-HT2A-mediated HTR (0.3–3 mg/kg s.c.) and 5-HT1A-mediated hypothermia and hypolocomotion (3–30 mg/kg s.c.).

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedSome affinity at 5-HT₂C is present for 4-substituted compounds, but lower than at 5-HT₂A.[13]model confidence 83%
Verified

Abstract measures 5-HT2A, 5-HT2C, 5-HT1A, and SERT and reports 'high selectivity for 5-HT2AR' for 4-substituted compounds. High selectivity for 5-HT2A when 5-HT2C was also measured implies lower (but present) affinity at 5-HT2C, supporting the claim.

21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedRickli et al. (2016) found that tryptamines including 4-OH-dipt — the closest structurally characterized analog to 4-HO-DET — interacted with the serotonin transporter (SERT) similarly to mdma[19]model confidence 85%
Verified

Abstract confirms that 'several tryptamines' interact with serotonin transporters, contrasted with mescaline (which does not) and compared alongside MDMA (which does). This supports the claim that tryptamines including structurally related 4-OH compounds interact with SERT similarly to MDMA.

Mescaline does not interact with serotonin, norepinephrine, or dopamine transporters — in contrast to MDMA and several tryptamines.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedSerotonergic psychedelics also interact with TrkB neurotrophin receptors, which may contribute to neuroplasticity effects[15]model confidence 95%
Verified

Abstract directly mentions TrkB receptors and neuroplasticity promotion as part of the reviewed psychedelic mechanisms, directly confirming the claim.

Review of psychedelic mechanisms beyond 5-HT2A including 5-HT1A, 5-HT2C, TrkB receptors. Neuroplasticity promotion reviewed.

checked by claude-sonnet-4-6 · Jul 17, 2026

neuroscience4 claims3verified1inconclusive
verifiedCameron et al. (2023) reviewed evidence that serotonergic psychedelics interact with TrkB neurotrophin receptors, promoting structural neuroplasticity via bdnf/mTOR signaling cascades[15]model confidence 82%
Verified

The abstract confirms TrkB receptors and neuroplasticity promotion are reviewed. BDNF/mTOR signaling is not specifically named in the abstract but is a standard downstream TrkB pathway; this is a reasonable inference from TrkB mention plus neuroplasticity.

Review of psychedelic mechanisms beyond 5-HT2A including 5-HT1A, 5-HT2C, TrkB receptors. Neuroplasticity promotion reviewed.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveThe psychoplastogen hypothesis proposes that psychedelics promote rapid structural neuroplasticity — dendritic arbor growth, spinogenesis, and synaptogenesis — via 5-HT₂A/TrkB/BDNF/mTOR signaling[15]model confidence 65%
Inconclusive

The abstract confirms TrkB receptors and neuroplasticity promotion are reviewed. However, the specific structural changes named (dendritic arbor growth, spinogenesis, synaptogenesis) and the full signaling cascade (5-HT₂A/TrkB/BDNF/mTOR) are not in the abstract. These specifics may be in the full paper but cannot be verified from the abstract alone.

Review of psychedelic mechanisms beyond 5-HT2A including 5-HT1A, 5-HT2C, TrkB receptors. Neuroplasticity promotion reviewed.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedCameron et al. (2023) reviewed evidence that serotonergic psychedelics interact with TrkB neurotrophin receptors, promoting structural neuroplasticity via bdnf/mTOR signaling cascades[15]model confidence 88%
Verified

Abstract directly confirms TrkB receptors and neuroplasticity promotion are reviewed. The specific BDNF/mTOR signaling cascade detail is not in the abstract but is the expected content of a TrkB-neuroplasticity review and is consistent with the abstract's stated scope.

Review of psychedelic mechanisms beyond 5-HT2A including 5-HT1A, 5-HT2C, TrkB receptors. Neuroplasticity promotion reviewed.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe psychoplastogen hypothesis proposes that psychedelics promote rapid structural neuroplasticity — dendritic arbor growth, spinogenesis, and synaptogenesis — via 5-HT₂A/TrkB/BDNF/mTOR signaling[15]model confidence 82%
Verified

Abstract confirms TrkB receptors and neuroplasticity promotion are covered in this review. The specific structural neuroplasticity details (dendritic arbor growth, spinogenesis, synaptogenesis) and signaling pathway (5-HT2A/TrkB/BDNF/mTOR) are the expected content of such a review. Per guidance, prefer 'supported' when the abstract is clearly about the right topic and doesn't contradict the claim.

Review of psychedelic mechanisms beyond 5-HT2A including 5-HT1A, 5-HT2C, TrkB receptors. Neuroplasticity promotion reviewed.

checked by claude-sonnet-4-6 · Jul 17, 2026

pharmacokinetic detail6 claims4verified2partial
verifiedAll parameters below are inferred by structural analogy to psilocin (4-HO-dmt), the best-characterized 4-hydroxytryptamine, via the systematic review of Meshkat et al. (2025).[14]model confidence 95%
Verified

The abstract is a systematic review of psilocybin/psilocin pharmacokinetics, confirming this is the appropriate citation for PK parameters inferred by analogy to psilocin.

Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans). Psilocin Tmax 1.8–4h; Cmax 8.2±2.8 to 871 ng/mL (dose-dependent); bioavailability 52.7±20%.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedRaithatha et al. (2024) found that 4-acetoxy prodrugs showed reduced pharmacological exposure compared to psilocybin (a phosphate ester prodrug), suggesting either slower hydrolysis, incomplete conversion, or different tissue distribution[1]model confidence 92%
Verified

Directly supported — the abstract states 'Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity,' and the mechanistic interpretations offered (slower hydrolysis, incomplete conversion, different distribution) are reasonable inferences.

Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialcyp2d6 is the primary metabolic enzyme for psilocin[14]model confidence 88%
Partial

The abstract states 'Primary metabolism by CYP2D6 and CYP3A4' — both are listed as co-primary enzymes. The claim singles out CYP2D6 as 'the primary' enzyme, which is a material simplification: the abstract does not rank CYP2D6 above CYP3A4 and lists both as primary.

Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedAll parameters below are inferred by structural analogy to psilocin (4-HO-dmt), the best-characterized 4-hydroxytryptamine, via the systematic review of Meshkat et al. (2025).[14]model confidence 95%
Verified

Abstract confirms this is a comprehensive systematic review of psilocybin/psilocin pharmacokinetics (14 studies, 112 healthy humans), making it the appropriate basis for analogy-based inference for structurally related 4-hydroxytryptamines.

Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans).

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedRaithatha et al. (2024) found that 4-acetoxy prodrugs showed reduced pharmacological exposure compared to psilocybin (a phosphate ester prodrug), suggesting either slower hydrolysis, incomplete conversion, or different tissue distribution[1]model confidence 95%
Verified

Abstract directly states 'Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.' The claim accurately represents this finding and offers reasonable mechanistic interpretations.

Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialcyp2d6 is the primary metabolic enzyme for psilocin[14]model confidence 82%
Partial

Abstract states 'Primary metabolism by CYP2D6 and CYP3A4' — both are listed as co-primary. The claim singles out CYP2D6 alone as 'the primary metabolic enzyme,' omitting CYP3A4 as an equally important primary enzyme. This is a material simplification that could be pharmacologically misleading.

Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.

checked by claude-sonnet-4-6 · Jul 17, 2026

effects overview2 claims1verified1inconclusive
inconclusiveNo controlled human studies have documented its subjective effects; all characterization derives from clinical reports on its active metabolite CZ-74 (4-ho-det) and community experience reports.[3]model confidence 60%
Inconclusive

The abstract covers the psycholytic therapy era and tryptamine use, which supports the 'clinical reports on CZ-74' component. However, the claim that 'no controlled human studies' exist for 4-AcO-DET cannot be confirmed from a positive abstract about a different substance. The abstract does not address 4-AcO-DET-specific studies.

Comprehensive review of psycholytic therapy 1949-1970s, led by Hanscarl Leuner in Germany. Various substances including tryptamines employed in serial lower-dose sessions.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedNo controlled human studies have documented its subjective effects; all characterization derives from clinical reports on its active metabolite CZ-74 (4-ho-det) and community experience reports.[3]model confidence 80%
Verified

Abstract describes clinical (non-controlled) use of tryptamines in psycholytic therapy sessions, consistent with the claim that available characterization comes from clinical reports rather than controlled studies. The absence of controlled data for 4-AcO-DET itself is not contradicted by the abstract.

Various substances including tryptamines employed in serial lower-dose sessions.

checked by claude-sonnet-4-6 · Jul 17, 2026

safety24 claims16verified2partial6inconclusive
inconclusiveNo animal toxicity studies specific to 4-AcO-DET were identified in the tryptamine toxicology reviews of Tittarelli et al. (2015) or Malaca et al. (2020).[20]model confidence 60%
Inconclusive

The abstract is a tryptamine toxicology review covering structure, pharmacology, recreational use, and toxicology — the right topic. However, it does not specifically mention 4-AcO-DET or confirm/deny the presence of animal toxicity data for this compound. An absence claim cannot be confirmed from a brief abstract.

Review of NPS tryptamines including structure, pharmacology, recreational use, toxicology, and analytical methods.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveNo animal toxicity studies specific to 4-AcO-DET were identified in the tryptamine toxicology reviews of Tittarelli et al. (2015) or Malaca et al. (2020).[21]model confidence 60%
Inconclusive

The abstract is a tryptamine toxicology review and confirms the right scope, but does not specifically address 4-AcO-DET or confirm the absence of animal toxicity data for it. The abstract's level of detail is insufficient to verify an absence claim.

Review of tryptamine toxicology; tryptamines are 5-HT2A agonists; DPT included; 22 new analytical methods 2015-2020; morbidity considerable and underestimated.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThis absence may reflect limited clinical detection rather than true absence of adverse events: Malaca et al. (2020) noted that tryptamine contribution to drug overdoses 'may be underestimated' because these compounds are not included in standard toxicology screening panels.[21]model confidence 85%
Verified

The abstract directly states 'morbidity considerable and underestimated,' supporting the core claim that adverse events are underestimated. The specific reason given (not in standard screening panels) is not in the abstract, but the underestimation claim itself is clearly supported.

morbidity considerable and underestimated.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedDe la Fuente Revenga et al. (2022) demonstrated in mice that rapid tolerance to 5-HT₂A-mediated head twitch response develops after a single dose, involves 5-HT₂A receptor downregulation in the frontal cortex, and produces cross-tolerance between psychedelics (doi and lsd were tested)[5]model confidence 97%
Verified

All three components of the claim are directly confirmed: tolerance after single dose, 5-HT₂AR downregulation in frontal cortex, and cross-tolerance between DOI and LSD.

Tolerance after single dose. Cross-tolerance between DOI and LSD. DOI caused 5-HT2AR downregulation in frontal cortex.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveGatch et al. (2011) found low reinforcement and low abuse-liability for related substituted tryptamines in rodent self-administration paradigms[22]model confidence 55%
Inconclusive

The abstract is about three substituted tryptamines' abuse liability (right topic), but the 'low abuse liability' statement in the abstract is attributed to DOM (a phenethylamine used as the training drug), not to the tryptamines themselves. DIPT 'fully substituted' for DOM as a discriminative stimulus, but this does not clearly indicate low abuse liability for the tryptamines. The abstract lacks enough detail to confirm the specific claim about tryptamine abuse liability.

DOM used as training drug. DIPT fully substituted at ED50=1.94 mg/kg. Low abuse liability for DOM in rodents.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe active metabolite 4-HO-DET is a 5-HT₂A agonist that may also interact with serotonin-transporter, creating multiple mechanistic pathways for serotonin-syndrome in combination settings.[19]model confidence 82%
Verified

The abstract confirms that several tryptamines (in contrast to mescaline) interact with the serotonin transporter, supporting SERT interaction for the tryptamine class. This creates the mechanistic basis for multi-pathway serotonin syndrome risk as claimed.

Mescaline does not interact with serotonin, norepinephrine, or dopamine transporters — in contrast to MDMA and several tryptamines.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedTramadol poses the most clearly documented danger. tramadol inhibits SERT, and Baldo (2018) identified it as among the opioids most associated with serotonin syndrome in humans[23]model confidence 88%
Verified

The abstract confirms tramadol inhibits human SERT and can precipitate serotonin syndrome when combined with serotonergic drugs. The claim about it being among opioids 'most associated' with serotonin syndrome is consistent with the abstract's focus on this mechanism.

Tramadol inhibits human SERT in HEK293 cells. Combined with serotonergic drugs (MAOIs, SSRIs), tramadol can precipitate serotonin syndrome.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedTramadol poses the most clearly documented danger. tramadol inhibits SERT, and Baldo (2018) identified it as among the opioids most associated with serotonin syndrome in humans[24]model confidence 85%
Verified

The abstract confirms tramadol inhibits serotonin reuptake and that its opioid effects compound serotonergic risk, supporting the claim about tramadol being a documented serotonin syndrome risk via SERT inhibition.

Tramadol inhibits serotonin reuptake and has opioid effects that compound serotonergic risk.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedTramadol poses the most clearly documented danger. tramadol inhibits SERT, and Baldo (2018) identified it as among the opioids most associated with serotonin syndrome in humans[23]model confidence 88%
Verified

Same as pair 18 — tramadol SERT inhibition and serotonin syndrome risk are directly confirmed in the abstract.

Tramadol inhibits human SERT in HEK293 cells. Combined with serotonergic drugs (MAOIs, SSRIs), tramadol can precipitate serotonin syndrome.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedCase reports confirm severe and prolonged serotonin toxicity from tramadol[25]model confidence 97%
Verified

The abstract is literally a case report of severe and prolonged serotonin toxicity from tramadol with a pharmacokinetic study, directly confirming the claim.

Case report of severe and prolonged serotonin toxicity from tramadol. Pharmacokinetic study confirming mechanism.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveCase reports confirm severe and prolonged serotonin toxicity from tramadol[24]model confidence 60%
Inconclusive

This is a pharmacodynamic review of tramadol-SSRI interactions, not a case report source. The abstract confirms serotonergic risk from tramadol but does not specifically confirm case reports of severe and prolonged serotonin toxicity. The claim's evidentiary framing ('case reports confirm') is not verifiable from this review abstract.

Reviews the pharmacodynamic basis of tramadol-SSRI serotonin syndrome interactions. Tramadol inhibits serotonin reuptake and has opioid effects that compound serotonergic risk.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedMonoamine oxidase inhibitors (MAOIs) would be expected to dramatically potentiate effects by inhibiting mao-a-mediated metabolic inactivation of the active metabolite 4-HO-DET[14]model confidence 88%
Verified

The abstract confirms MAO-A as a secondary metabolic enzyme for psilocin. By analogy to 4-HO-DET (a structurally similar 4-hydroxytryptamine), MAO-A inhibition by MAOIs would be expected to potentiate effects — a reasonable inference from this data.

Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveNo animal toxicity studies specific to 4-AcO-DET were identified in the tryptamine toxicology reviews of Tittarelli et al. (2015) or Malaca et al. (2020).[20]model confidence 60%
Inconclusive

The abstract confirms this is a review of NPS tryptamine toxicology, making it appropriate to cite for toxicological coverage. However, whether 4-AcO-DET specifically appears or is absent cannot be verified from the abstract alone — that determination requires reading the full paper's compound list.

Review of NPS tryptamines including structure, pharmacology, recreational use, toxicology, and analytical methods.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveNo animal toxicity studies specific to 4-AcO-DET were identified in the tryptamine toxicology reviews of Tittarelli et al. (2015) or Malaca et al. (2020).[21]model confidence 60%
Inconclusive

The abstract confirms this is a tryptamine toxicology review (2015-2020 scope), making it an appropriate source for toxicological coverage claims. However, whether 4-AcO-DET specifically is absent from the paper's compound coverage cannot be verified from the abstract text alone.

Review of tryptamine toxicology; tryptamines are 5-HT2A agonists; DPT included; 22 new analytical methods 2015-2020.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThis absence may reflect limited clinical detection rather than true absence of adverse events: Malaca et al. (2020) noted that tryptamine contribution to drug overdoses "may be underestimated" because these compounds are not included in standard toxicology screening panels.[21]model confidence 88%
Verified

Abstract explicitly mentions 'morbidity considerable and underestimated,' directly supporting the claim that tryptamine adverse event contribution is underestimated. The reason (not included in standard panels) is a reasonable inference from the analytical methods focus of the review.

morbidity considerable and underestimated.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedDe la Fuente Revenga et al. (2022) demonstrated in mice that rapid tolerance to 5-HT₂A-mediated head twitch response develops after a single dose, involves 5-HT₂A receptor downregulation in the frontal cortex, and produces cross-tolerance between psychedelics (doi and lsd were tested)[5]model confidence 97%
Verified

All three specific assertions are directly confirmed by the abstract: (1) tolerance after single dose, (2) 5-HT2AR downregulation in frontal cortex, (3) cross-tolerance between DOI and LSD.

Tolerance after single dose. Cross-tolerance between DOI and LSD. DOI caused 5-HT2AR downregulation in frontal cortex.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialGatch et al. (2011) found low reinforcement and low abuse-liability for related substituted tryptamines in rodent self-administration paradigms[22]model confidence 70%
Partial

The abstract states 'Low abuse liability for DOM in rodents,' but DOM is a substituted phenethylamine, not a tryptamine. DIPT (a tryptamine) is mentioned as fully substituting for DOM in drug discrimination but the abstract's stated low-abuse-liability conclusion is attributed to DOM, not to the tryptamines. The claim attributes this conclusion to 'substituted tryptamines' which is not precisely what the abstract confirms.

DOM used as training drug. DIPT fully substituted at ED50=1.94 mg/kg. Low abuse liability for DOM in rodents.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe active metabolite 4-HO-DET is a 5-HT₂A agonist that may also interact with serotonin-transporter, creating multiple mechanistic pathways for serotonin-syndrome in combination settings.[19]model confidence 87%
Verified

Abstract confirms that tryptamines (unlike mescaline) interact with monoamine transporters including serotonin transporter, supporting the claim that 4-HO-DET (a tryptamine) may interact with SERT as an additional serotonin syndrome risk pathway.

Mescaline does not interact with serotonin, norepinephrine, or dopamine transporters — in contrast to MDMA and several tryptamines.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedTramadol poses the most clearly documented danger. tramadol inhibits SERT, and Baldo (2018) identified it as among the opioids most associated with serotonin syndrome in humans[23]model confidence 88%
Verified

Abstract directly confirms tramadol inhibits human SERT and can precipitate serotonin syndrome when combined with serotonergic drugs. The 'most associated' framing is not explicitly in the abstract but is not contradicted, and the mechanism and risk are clearly confirmed.

Tramadol inhibits human SERT in HEK293 cells. Combined with serotonergic drugs (MAOIs, SSRIs), tramadol can precipitate serotonin syndrome.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedTramadol poses the most clearly documented danger. tramadol inhibits SERT, and Baldo (2018) identified it as among the opioids most associated with serotonin syndrome in humans[24]model confidence 85%
Verified

Abstract confirms tramadol inhibits serotonin reuptake and poses serotonin syndrome risk compounded by its opioid effects. The core claim about tramadol SERT inhibition and serotonin syndrome danger is well supported.

Tramadol inhibits serotonin reuptake and has opioid effects that compound serotonergic risk.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedTramadol poses the most clearly documented danger. tramadol inhibits SERT, and Baldo (2018) identified it as among the opioids most associated with serotonin syndrome in humans[23]model confidence 88%
Verified

Abstract directly confirms tramadol inhibits human SERT and precipitates serotonin syndrome with serotonergic drug combinations. Core claim is well supported.

Tramadol inhibits human SERT in HEK293 cells. Combined with serotonergic drugs (MAOIs, SSRIs), tramadol can precipitate serotonin syndrome.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedCase reports confirm severe and prolonged serotonin toxicity from tramadol[25]model confidence 97%
Verified

Abstract is a case report that directly describes 'severe and prolonged serotonin toxicity from tramadol' — an exact match to the claim.

Case report of severe and prolonged serotonin toxicity from tramadol. Pharmacokinetic study confirming mechanism.

checked by claude-sonnet-4-6 · Jul 17, 2026

partialCase reports confirm severe and prolonged serotonin toxicity from tramadol[24]model confidence 72%
Partial

This citation is a pharmacodynamic review of tramadol-SSRI interactions, not a case report. The abstract confirms serotonin syndrome risk from tramadol but does not specifically describe case reports or characterize toxicity as 'severe and prolonged.' The 'case reports confirm' framing is better attributed to citation [31] (the actual case report); this review provides mechanistic support only.

Reviews the pharmacodynamic basis of tramadol-SSRI serotonin syndrome interactions. Tramadol inhibits serotonin reuptake and has opioid effects that compound serotonergic risk.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedMonoamine oxidase inhibitors (MAOIs) would be expected to dramatically potentiate effects by inhibiting mao-a-mediated metabolic inactivation of the active metabolite 4-HO-DET[14]model confidence 90%
Verified

Abstract confirms MAO-A is a secondary metabolic pathway for psilocin (the structural analog being used for inference). Inhibition of MAO-A would reduce clearance of the 4-hydroxy metabolite, supporting the potentiation claim by analogy.

Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.

checked by claude-sonnet-4-6 · Jul 17, 2026

clinical evidence2 claims2verified
verifiedThe active metabolite CZ-74 was employed in clinical psycholytic therapy during the 1960s by Hanscarl Leuner and colleagues at approximately 30 European treatment centers[3]model confidence 88%
Verified

The abstract confirms Leuner led psycholytic therapy in Germany at 30 European clinical centers with various tryptamines. CZ-74 is not named specifically in the abstract but the historical context is confirmed.

Comprehensive review of psycholytic therapy 1949-1970s, led by Hanscarl Leuner in Germany. Used at 30 European clinical centers. Various substances including tryptamines employed in serial lower-dose sessions.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedThe active metabolite CZ-74 was employed in clinical psycholytic therapy during the 1960s by Hanscarl Leuner and colleagues at approximately 30 European treatment centers[3]model confidence 90%
Verified

Abstract directly confirms Leuner led psycholytic therapy at 30 European clinical centers using tryptamines during the covered period, supporting all key historical facts in the claim.

Comprehensive review of psycholytic therapy 1949-1970s, led by Hanscarl Leuner in Germany. Used at 30 European clinical centers. Various substances including tryptamines employed in serial lower-dose sessions.

checked by claude-sonnet-4-6 · Jul 17, 2026

comparative pharmacology8 claims6verified2inconclusive
verifiedGlatfelter et al. (2023) tested both N,N-diethyl and N,N-dimethyl 4-substituted tryptamines and found similar target profiles across serotonin receptors, though specific Ki values for 4-AcO-DET were not reported. 4-AcO-DMT has more extensive pharmacological characterization, including demonstrated nanomolar affinity for 5-ht2a and 5-ht1a.[16]model confidence 80%
Verified

The abstract confirms that 4-acetoxy analogues of 4-hydroxy compounds show 'similar target profiles across 5-HT receptors,' supporting the core claim. N,N-diethyl specific testing and 4-AcO-DMT nanomolar affinity are not confirmed by this abstract but also not contradicted.

4-Acetoxy and 4-propionoxy analogues of 4-hydroxy compounds displayed somewhat weaker binding affinities but similar target profiles across 5-HT receptors and other identified targets.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedGlatfelter et al. (2023) tested both N,N-diethyl and N,N-dimethyl 4-substituted tryptamines and found similar target profiles across serotonin receptors, though specific Ki values for 4-AcO-DET were not reported. 4-AcO-DMT has more extensive pharmacological characterization, including demonstrated nanomolar affinity for 5-ht2a and 5-ht1a.[17]model confidence 78%
Verified

The abstract confirms psilacetin (4-AcO-DMT) as a prodrug for psilocin and that 4-acetoxy and 4-hydroxy compounds show 'similar pharmacological effects,' supporting the comparative pharmacology context. The claim about 4-AcO-DMT's nanomolar binding is not in this abstract but is not contradicted.

4-Acetoxy and 4-hydroxy compounds showed similar pharmacological effects. Psilacetin (4-AcO-DMT) acts as prodrug for psilocin.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedRaithatha et al. (2024) demonstrated that acetate ester prodrugs showed reduced pharmacological exposure compared with psilocybin, suggesting the phosphate ester is a more efficient delivery mechanism.[1]model confidence 90%
Verified

Directly supported — the abstract states reduced pharmacological exposure vs psilocybin (a phosphate ester), and the inference about delivery efficiency is reasonable.

Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedMcKenna et al. (1990) established that N,N-dialkyl group size influences 5-HT₂A binding affinity[6]model confidence 97%
Verified

The abstract directly states 'N,N-dialkyl size secondary determinant; groups larger than diisopropyl markedly reduce affinity,' confirming that N,N-dialkyl group size influences 5-HT₂A binding affinity.

N,N-dialkyl size secondary determinant; groups larger than diisopropyl markedly reduce affinity.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveGlatfelter et al. (2023) tested both N,N-diethyl and N,N-dimethyl 4-substituted tryptamines and found similar target profiles across serotonin receptors, though specific Ki values for 4-AcO-DET were not reported. 4-AcO-DMT has more extensive pharmacological characterization, including demonstrated nanomolar affinity for 5-ht2a and 5-ht1a.[16]model confidence 60%
Inconclusive

Abstract confirms similar target profiles for 4-acetoxy analogues, supporting part of the claim. However, whether N,N-diethyl specifically was tested, whether 4-AcO-DET Ki values were specifically not reported, and whether 4-AcO-DMT has 'more extensive characterization' including nanomolar affinity cannot be confirmed from the abstract alone.

4-Acetoxy and 4-propionoxy analogues of 4-hydroxy compounds displayed somewhat weaker binding affinities but similar target profiles across 5-HT receptors.

checked by claude-sonnet-4-6 · Jul 17, 2026

inconclusiveGlatfelter et al. (2023) tested both N,N-diethyl and N,N-dimethyl 4-substituted tryptamines and found similar target profiles across serotonin receptors, though specific Ki values for 4-AcO-DET were not reported. 4-AcO-DMT has more extensive pharmacological characterization, including demonstrated nanomolar affinity for 5-ht2a and 5-ht1a.[17]model confidence 60%
Inconclusive

Abstract confirms 4-acetoxy and 4-hydroxy compounds have similar pharmacological effects and that 4-AcO-DMT (psilacetin) acts as a prodrug for psilocin. However, the abstract is behavioral (SAR in mice), not receptor binding — 'nanomolar affinity for 5-HT2A and 5-HT1A' is not confirmed here. The claim about more extensive characterization cannot be evaluated from this abstract.

4-Acetoxy and 4-hydroxy compounds showed similar pharmacological effects. Psilacetin (4-AcO-DMT) acts as prodrug for psilocin.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedRaithatha et al. (2024) demonstrated that acetate ester prodrugs showed reduced pharmacological exposure compared with psilocybin, suggesting the phosphate ester is a more efficient delivery mechanism.[1]model confidence 93%
Verified

Abstract directly confirms reduced pharmacological exposure vs psilocybin for 4-acetoxy prodrugs, supporting the comparison. The inference about phosphate ester efficiency is a reasonable interpretation of the finding.

Novel prodrugs showed reduced pharmacological exposure vs psilocybin while retaining psilocin activity.

checked by claude-sonnet-4-6 · Jul 17, 2026

verifiedMcKenna et al. (1990) established that N,N-dialkyl group size influences 5-HT₂A binding affinity[6]model confidence 97%
Verified

Abstract directly confirms 'N,N-dialkyl size secondary determinant' and 'groups larger than diisopropyl markedly reduce affinity' — this directly establishes N,N-dialkyl group size as an influence on 5-HT2A binding affinity.

N,N-dialkyl size secondary determinant; groups larger than diisopropyl markedly reduce affinity.

checked by claude-sonnet-4-6 · Jul 17, 2026

05

Coverage & Gaps

effect links
191 links · 191 approved · 49 audited0/191 with evidence basis
interactions
2 approved pairs0/2 graded
06

Research Trail

substance-article pipeline-v5 Apr 28, 2026

StepSourceQueryResults
1database lookupPubChem4-AcO-DET1 result, 1 selected
selection rationale

Only result; confirms chemical identity data from seed brief.

2literature searchPubMed4-AcO-DET ethacetin diethyltryptamine acetate pharmacology0 results
selection rationale

discarded 0: No results.

3literature searchOpenAlex4-acetoxy-DET ethacetin tryptamine psychedelic0 results
selection rationale

discarded 0: no summary recorded

4clinical trial searchClinicalTrials.gov4-AcO-DET ethacetin0 results
5literature searchPubMedsubstituted tryptamine serotonin 5-HT2A receptor binding affinity psychedelic15 results, 4 selected
6literature searchOpenAlexdiethyltryptamine DET psychedelic serotonin receptor10 results, 4 selected
7literature searchPubMed4-acetoxy tryptamine psilocin prodrug serotonin receptor1 result, 1 selected
8literature searchPubMedtryptamine serotonin syndrome drug interaction tramadol8 results, 2 selected
9literature searchPubMedtryptamine psychedelic cross tolerance serotonin 5-HT2A receptor downregulation1 result, 1 selected
10document retrievalPsychonautWiki4-AcO-DET pharmacology dosage1 result
selection rationale

Cross-reference for dose data.

11document retrievalWikidoc4-AcO-DET history synthesis legal status1 result, 3 selected
selection rationale

Primary historical data about 4-AcO-DET first synthesis.

12document retrievalErowid4-AcO-DET stability degradation1 result, 3 selected
selection rationale

Key stability and market history data.

13web searchWeb4-AcO-DET UK legal status scheduling tryptamine10 results, 3 selected
14literature searchPubMedpsilocybin psilocin pharmacokinetics CYP metabolism human1 result, 1 selected
15literature searchPubMedpsychedelic tryptamine head twitch drug discrimination rat mouse4 results, 3 selected
16literature searchOpenAlex4-acetoxy tryptamine prodrug psilocin 5-HT2A receptor8 results, 3 selected
17document retrievalMAPS/webLeuner CZ-74 clinical psycholytic therapy1 result
selection rationale

Historical context for CZ-74/4-HO-DET clinical use.

18legal status searchWeb/GOV.UKUK Psychoactive Substances Act 2016 tryptamine10 results, 2 selected
19literature searchPubMednovel psychoactive substance tryptamine intoxication emergency department1 result, 1 selected
20cross referencePubChem/Wikidoc/Erowid4-AcO-DET chemical identity cross-reference3 results
selection rationale

Verifying all chemical identity data against primary source.

Research document (raw, unedited pipeline output)
# Research Output: 4-AcO-DET (Ethacetin)

**Substance:** 4-AcO-DET / Ethacetin / Ethylacybin  
**PSX ID:** PSX-0056  
**Research date:** 2026-04-27  
**Readiness assessment:** Sparse (emerging substance; no human clinical trials or PK studies specific to 4-AcO-DET; most data derives from structural analogs and class-level research)

---

## Chemical Identity

**Confirmed via PubChem CID 24801867 [Ref 1]:**

| Field | Value |
|---|---|
| IUPAC name | [3-[2-(diethylamino)ethyl]-1H-indol-4-yl] acetate |
| Molecular formula | C₁₆H₂₂N₂O₂ |
| Molecular weight | 274.36 g/mol |
| InChIKey | WYEVVQJLTXBMPM-UHFFFAOYSA-N |
| PubChem CID | 24801867 |

**Discrepancies with seed brief:** The brief listed SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID all as empty. These have now been confirmed from PubChem [Ref 1]. The IUPAC name in the brief ("systematic name") matches PubChem exactly. The brief's MW field was empty; it is confirmed as 274.36 g/mol.

**CAS number:** A CAS number for 4-AcO-DET specifically was not located in published sources. The related compound 4-HO-DET (the active metabolite) carries CAS 22204-89-3 [Ref 24].

**Chemical class note:** 4-AcO-DET is the acetate ester of 4-HO-DET (ethocin), which is itself a 4-substituted tryptamine structurally analogous to psilocin (4-HO-DMT). The relationship: 4-AcO-DET → (serum esterase hydrolysis) → 4-HO-DET → (CYP/MAO metabolism) → metabolic products.

**⚠️ FLAG — CAS number not confirmed from primary source; flag for editorial verification.**

---

## Pharmacology

### Mechanism of Action

4-AcO-DET is presumed to be a prodrug that undergoes hydrolysis via serum esterases to yield 4-HO-DET (ethocin/CZ-74) [Ref 17, Ref 21]. This mechanism parallels psilocybin → psilocin conversion and is supported by GCMS analysis of degraded 4-AcO-DET samples, which revealed 4-HO-DET as the primary product [Ref 17]. The 4-hydroxy metabolite 4-HO-DET is the pharmacologically active species acting as a 5-HT₂A receptor agonist.

**Important caveat:** Shulgin noted that 4-AcO-DET may possess independent pharmacological activity beyond functioning solely as a prodrug, citing "faster onset and increased potency" observations from group studies [Ref 17, Ref 28]. Raithatha et al. (2024) demonstrated that 4-acetoxy groups on indole tryptamines do function as cleavable prodrug moieties generating the active 4-hydroxy form, but noted that 4-acetoxy compounds show "somewhat weaker binding affinities but similar target profiles across 5-HT receptors" compared to their 4-OH counterparts [Ref 21]. This introduces the possibility that some direct 5-HT₂A agonism by 4-AcO-DET itself may occur prior to hydrolysis, in addition to activity via 4-HO-DET.

**⚠️ FLAG — No direct receptor binding data (Ki/EC₅₀) has been published specifically for 4-AcO-DET. All pharmacology must be inferred from analogs. This is a safety-critical gap.**

### Primary Receptor Target: 5-HT₂A

The primary psychedelic mechanism is 5-HT₂A receptor agonism [Ref 4, Ref 23]. Multiple lines of evidence support this:

- **Kozell et al. (2023)** [Ref 4] characterized 21 substituted tryptamines at 5-HT₁A, 5-HT₂A, 5-HT₂C, and SERT using human-receptor-expressing HEK cells. They found that 4-substituted tryptamines exhibited "high selectivity for 5-HT₂ARs versus 5-HT₁ARs and 5-HT₂CRs," with affinities spanning a 100-fold range across 4-substituted compounds, including specific testing of 4-acetoxy compounds.

- **Glatfelter et al. (2023)** [Ref 2] determined receptor binding profiles across multiple tryptamines with different 4-position substituents (hydroxy, acetoxy, propionoxy) and N,N-dialkyl substitutions including **N,N-diethyl** (directly relevant to 4-AcO-DET). They found: "4-Acetoxy and 4-propionoxy analogues of 4-hydroxy compounds displayed somewhat weaker binding affinities but similar target profiles across 5-HT receptors and other identified targets." The tryptamine psychedelics targeted multiple serotonin receptors including 5-HT₁A.

- **McKenna et al. (1990)** [Ref 7] showed 4-hydroxylated indolealkylamines have 25–380-fold selectivity for the 5-HT₂A site over 5-HT₁A. N,N-dialkyl group size was a secondary determinant of affinity; groups larger than N,N-diisopropyl markedly reduced affinity, meaning N,N-diethyl (smaller than diisopropyl) should retain substantial affinity.

- **Glatfelter et al. (2022)** [Ref 3] showed in mouse models that 4-acetoxy tryptamines (psilacetin/4-AcO-DMT was specifically tested) display "nanomolar affinity for most human 5-HT receptor subtypes tested, including the 5-HT₂A and the serotonin 1A receptor." Tertiary amines (like 4-AcO-DET with its N,N-diethyl group) induced head twitch response (HTR) in mice, indicative of 5-HT₂A-mediated psychedelic activity; 5-HT₂A antagonist pretreatment blocked HTR.

### Additional Receptor Targets

Based on class-level data for 4-hydroxylated and 4-acetoxylated N,N-dialkyl tryptamines:

- **5-HT₁A:** Secondary agonist activity at 5-HT₁A receptors is documented for the class (Rickli et al. 2016 [Ref 19]; Glatfelter et al. 2023 [Ref 2]). At high doses, 5-HT₁A activation attenuates the 5-HT₂A-mediated head twitch response and produces hypothermia and hypolocomotion in mice [Ref 2].

- **5-HT₂C:** Some affinity at 5-HT₂C, but lower than at 5-HT₂A for 4-substituted compounds [Ref 4].

- **SERT:** Rickli et al. (2016) [Ref 19] found that tryptamines including 4-OH-DiPT (the closest structurally characterized analog to 4-HO-DET) interacted with the serotonin transporter (SERT) similarly to MDMA. This is a clinically relevant finding because it could contribute to serotonergic interactions.

- **Cameron et al. (2023)** [Ref 23] reviews that serotonergic psychedelics also interact with TrkB neurotrophin receptors, which may contribute to neuroplasticity effects, though this has not been studied for 4-AcO-DET specifically.

### Functional Selectivity (Biased Signaling)

Wallach et al. (2023) [Ref in OpenAlex] showed that 5-HT₂A-Gq (not β-arrestin2) signaling predicts psychedelic potential, with a threshold level of Gq activation required. This Gq-biased signaling model applies to the class of 4-substituted tryptamines and is relevant for understanding why 4-AcO-DET produces full psychedelic effects.

### Pharmacokinetics

**No published human pharmacokinetic data exists for 4-AcO-DET.** The following is inferred from the closest analogs:

**Prodrug hydrolysis:** 4-AcO-DET is believed to undergo rapid hydrolysis to 4-HO-DET via serum esterases [Ref 17, Ref 21]. The rate of this hydrolysis in humans has not been published. Raithatha et al. (2024) [Ref 21] showed that 4-acetoxy compounds showed "reduced pharmacological exposure compared with psilocybin" as prodrugs, suggesting slower or less-complete activation than phosphate esters.

**Metabolic pathway (by analogy to psilocin):** Meshkat et al. (2025) [Ref 13] systematic review of psilocybin pharmacokinetics (14 studies, 112 humans) found that psilocin (4-HO-DMT, the direct structural analog to 4-HO-DET) is metabolized primarily by **CYP2D6 and CYP3A4** with secondary contribution from **monoamine oxidase A (MAO-A)**. Elimination half-life: 1.5–4 hours. Tmax: 1.8–4 hours following oral administration. Bioavailability: 52.7 ± 20%. Primary metabolites: 4-hydroxyindole-3-acetic acid (4-HIAA) and 4-hydroxytryptophol.

By structural analogy, 4-HO-DET (and thus 4-AcO-DET) likely follows the same metabolic pathway. However, the larger N,N-diethyl group (vs. N,N-dimethyl in psilocin) may alter substrate affinity for CYP2D6.

**⚠️ FLAG — All pharmacokinetic data for 4-AcO-DET is by analogy. No human PK study has been published. This is a critical gap for safety-critical dose-related claims.**

---

## History

### Discovery and Synthesis

**4-HO-DET (CZ-74/Ethocin) — the active metabolite:** Was synthesized at Sandoz Laboratories, Basle, Switzerland in the late 1950s by **Albert Hofmann and Franz Troxler** [Ref 24, Ref 20]. Its Sandoz code designation was **CZ-74**. It was developed alongside its phosphoryloxy analog CEY-19 (ethocybin/4-PO-DET) as short-acting psilocybin derivatives.

**4-AcO-DET (Ethacetin) — the acetate ester:** First synthesized in **1958 by Albert Hofmann** at Sandoz [Ref 16], apparently as part of a systematic exploration of 4-substituted tryptamine esters following the discovery of psilocybin and psilocin in 1958–1960.

**DET (the core scaffold):** N,N-diethyltryptamine itself was first synthesized by **Stephen Szára** and first reported in published literature in **1957** [Ref 8 by class; web-retrieved]. Szára and colleagues conducted early human studies with DET in the early 1960s, using intramuscular doses of approximately 1–2 mg/kg, documenting visual distortions, altered perception, and anxiety as part of psychotomimetic research.

### Clinical History of CZ-74 (4-HO-DET)

CZ-74 was studied in human clinical research in the 1960s. **Hanscarl Leuner** (University of Göttingen, Germany) and **G. Baer** conducted clinical trials with CZ-74 and CEY-19 in the context of **psycholytic therapy** — a European form of psychedelic-assisted psychotherapy [Ref 20, Ref 25]. Leuner was the leading figure in European psycholytic therapy, heading the European Medical Society for Psycholytic Therapy (EPT), and the substances were employed at approximately 30 clinical treatment centers across Europe.

G. Baer's 1967 dissertation specifically covered clinical safety and psychopathological studies of CZ-74 and CEY-19 [Ref 25 — web-retrieved; unverifiable as primary source]. CZ-74 was described as producing "virtually no side-effects" at therapeutic doses [Ref 25].

Shulgin subsequently described both 4-HO-DET and its acetate ester 4-AcO-DET in **TiHKAL: Tryptamines I Have Known and Loved** (1997) [Ref 28], entry #16 "4-HO-DET," noting oral doses of 10–25 mg and duration of 2–6 hours. The acetate ester was noted as a presumed prodrug with possibly independent activity.

### Research Chemical Market

4-AcO-DET first appeared on the research chemical market in **May 2001**, when it was introduced to a research chemical vendor's product inventory [Ref 17 — Erowid document]. The compound was marketed as "ethacetin" (or "ethylacybin"). The Passie et al. (2022) review [Ref 20] provides historical context on the broader psycholytic therapy era from which these compounds emerged.

### Regulatory History

- DET (the parent compound) was placed in **Schedule I of the UN 1971 Convention on Psychotropic Substances** [Ref 30].
- DET is also **Schedule I in the United States** (DEA code 7434) [Ref 30].
- In January 2022, the DEA proposed scheduling the related compound 4-OH-DiPT (and four others: 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT, DiPT) in Schedule I, but withdrew the proposed rule in July 2022 following significant public comment and referred the matter to HHS for updated evaluation [Ref 29]. This withdrawal preserved the legal ambiguity of 4-AcO-DET in the US.

---

## Subjective Effects

**No published controlled human studies exist for 4-AcO-DET.** The following is based on: (a) clinical documentation of CZ-74 (4-HO-DET) by Leuner [Ref 20, Ref 25]; (b) TiHKAL [Ref 28]; (c) class-level knowledge from structurally related psychedelics; and (d) community reports (labelled as such).

### Effects Documented in Clinical Literature (for CZ-74/4-HO-DET)

Leuner and colleagues used CZ-74 in a psycholytic therapy context and documented it as producing psychedelic effects qualitatively similar to psilocin and psilocybin but with a **shorter duration** [Ref 20, Ref 25, Ref 28]. The experience was described as suitable for psychotherapeutic work due to its manageable duration.

### Effect Profile (from Seed Brief — User-Report Origin, Unverified)

The following effect categories from the seed brief are consistent with the 5-HT₂A agonist class mechanism and the CZ-74 clinical record, but are sourced from user reports rather than controlled studies:

**Body effects:** Nasal congestion, restlessness, watery eyes, appetite suppression, dizziness, bodily pressures, increased urination, spontaneous body sensations, bruxism, abnormal heartbeat, nausea, yawning, dehydration sensation, sedation, temperature dysregulation, wakefulness, muscle tension, pupil dilation, headache.

**Perceptual effects:** After-images, tracers, object transformations, color alteration, symmetrical texture repetition, visual diffraction, perspective distortion, color enhancement, internal hallucinations, depth perception distortion, music enhancement, visual acuity enhancement, brightness alteration, visual drifting.

**Temporal effects:** Time alteration, déjà vu.

**Emotional/transpersonal effects:** Emotional enhancement, non-dual awareness, entity contact, unity and interconnectedness, transpersonal feelings.

**Cognitive effects:** Delusions, novelty enhancement, thought connectivity, pattern recognition enhancement, thought loops, conceptual thinking, immersion enhancement, memory suppression, personal insight.

These effect categories are broadly consistent with the 5-HT₂A receptor agonist mechanism documented by Halberstadt et al. (2020) [Ref 14] and the general tryptamine psychedelic profile.

### Duration

Seed data (oral): Onset 20–60 min, come-up 1–1.5 h, peak 1.5–3 h, offset 1–2 h, aftereffects 2–4 h, total 4–7 h.

TiHKAL [Ref 28] lists 4-HO-DET duration as 2–6 hours (orally), and describes it as shorter than psilocin/psilocybin. The acetate ester form (4-AcO-DET) would require additional time for prodrug hydrolysis, potentially extending the onset phase. The seed brief's 4–7 hour total is plausible and somewhat longer than TiHKAL's 4-HO-DET estimate, consistent with added prodrug hydrolysis time. This cannot be resolved without human PK data.

**⚠️ FLAG — Duration data in the brief has not been confirmed in controlled human studies. Inferred from analog (4-HO-DET) and user reports.**

### Dose

Seed brief (oral): Threshold 5 mg, Light 10–15 mg, Common 15–20 mg, Strong 20–35 mg, Heavy 35+ mg.

Shulgin lists 10–25 mg for 4-HO-DET (the active form) [Ref 28]. DMT-Nexus wiki lists 4-HO-DET tentative doses as 2–25 mg [Ref 24]. Given that 4-AcO-DET has MW 274.36 vs. 4-HO-DET MW 232.32 (ratio ≈ 1.18), an equivalent weight of 4-AcO-DET delivers ~85% of the molar amount of active 4-HO-DET. The brief's common dose of 15–20 mg for 4-AcO-DET is therefore broadly consistent with Shulgin's 10–25 mg for 4-HO-DET, assuming complete conversion. The seed dose data appears reasonable.

**⚠️ FLAG — Dose ranges are not verified in any published human study. Based on TiHKAL and community reports.**

---

## Safety & Toxicity

### LD50 / Toxic Dose

No LD50 data has been published for 4-AcO-DET in any species. The seed brief states "toxic dose is unknown," which is accurate and should be retained. No animal toxicity studies specific to 4-AcO-DET were identified in the literature [Ref 5, Ref 6].

### Adverse Event Case Reports

No published case reports of adverse events, overdose, or toxicity specific to 4-AcO-DET were identified in PubMed, OpenAlex, or the Tittarelli (2015) [Ref 5] or Malaca (2020) [Ref 6] tryptamine toxicology reviews.

**⚠️ FLAG — Absence of case reports may reflect limited clinical detection capability rather than absence of adverse events. The Malaca (2020) review [Ref 6] notes that tryptamine contribution to drug overdoses "may be underestimated" and that they are not part of typical toxicology testing regimens.**

### Physical Stability and Degradation Hazard

4-AcO-DET degrades upon exposure to air, light, and moisture. Degradation progresses from tan powder to black tarry substance over months. GCMS analysis of degraded samples identified the primary degradation product as 4-HO-DET, with secondary unidentified compounds ("C and D") with unknown activity. The mechanism is likely polymerization rather than simple oxidation [Ref 17]. Degraded samples may retain significant potency. Storage recommendation: airtight, frozen, dry conditions; consider oxygen absorbers and silica gel. Converting to a salt form may improve stability [Ref 17].

**⚠️ FLAG — Unidentified degradation products ("C and D") in aged samples have unknown toxicological profiles. This is a potential safety concern not previously flagged in the brief.**

### Psychological Risks

The psychedelic class risk profile includes anxiety, panic reactions, psychological decompensation in vulnerable individuals, and persisting perception disorders (HPPD). No published data specific to 4-AcO-DET exists. General psychedelic adverse psychological event data applies by class inference.

---

## Harm Reduction

### Stability and Testing

4-AcO-DET is chemically unstable and prone to degradation [Ref 17]. Samples should be stored airtight in frozen, dark, dry conditions. Degraded (discolored) samples should be approached with caution as they may contain unknown active components beyond 4-HO-DET [Ref 17].

**Reagent testing:** 4-AcO-DET (and its metabolite 4-HO-DET) should produce color reactions with Ehrlich reagent (characteristic of indoles) and Simon's reagent (secondary vs. tertiary amines). NMR reference spectra for 4-acetoxy tryptamines from grey-market samples exist in Chapman (2017) [Ref 22], providing analytical reference for forensic and harm-reduction identification purposes.

### Set and Setting

No published harm reduction guidelines specific to 4-AcO-DET exist. Standard psychedelic harm reduction applies: appropriate setting, trusted companions, no mixing with serotonergic or stimulant drugs, avoidance in individuals with personal/family history of psychosis or schizophrenia.

### Contraindications

No published contraindication data specific to 4-AcO-DET. Class-level contraindications based on 5-HT₂A agonism mechanism:
- Personal or family history of psychosis, schizophrenia, or bipolar disorder
- Concurrent serotonergic medication (see Interactions)
- Cardiovascular disease (tachycardia, blood pressure elevation risk)
- Pregnancy/nursing (no safety data)

---

## Tolerance & Dependence

### Tolerance

The seed brief states: buildup "almost immediately after ingestion," half-life "3 days," full reset "7 days," cross-tolerances "psychedelic."

This is consistent with the mechanism of 5-HT₂A receptor downregulation documented for the psychedelic class. de la Fuente Revenga et al. (2022) [Ref 10] demonstrated in mice that:
- Rapid tolerance to 5-HT₂A-mediated HTR develops after even a single dose
- Cross-tolerance was observed between psychedelics DOI and LSD
- Tolerance involves 5-HT₂A receptor downregulation in frontal cortex
- Non-psychedelic 5-HT₂A agonists (lisuride) did NOT produce tolerance, confirming the mechanism requires the full psychedelic receptor engagement

The seed brief's 3-day half-life and 7-day full reset are consistent with literature for the psychedelic class and are empirically reasonable, though not validated specifically for 4-AcO-DET.

### Dependence

The seed brief states "not habit-forming." This is consistent with the class profile. Gatch et al. (2011) [Ref 9] found low reinforcing effects and low abuse liability for related substituted tryptamines in rodent self-administration models. The mechanism of rapid tolerance makes compulsive daily use pharmacologically self-limiting.

**⚠️ FLAG — No substance-specific dependence data for 4-AcO-DET. Inferred from class.**

---

## Interactions

### Tramadol — DANGEROUS

The seed brief flags tramadol as a dangerous interaction. This is pharmacologically well-supported:

1. Tramadol inhibits SERT (serotonin reuptake transporter) [Ref 11, Ref 12]
2. 4-AcO-DET and its active metabolite 4-HO-DET are 5-HT₂A agonists and may also interact with SERT (as documented for the 4-OH-DiPT analog by Rickli et al. 2016 [Ref 19])
3. Baldo (2018) [Ref 11] comprehensively reviews opioid-serotonin toxicity mechanisms, confirming tramadol is among the opioids most associated with serotonin syndrome in humans
4. Case reports confirm severe and prolonged serotonin toxicity from tramadol alone [Ref 32] and in combination with serotonergic agents [Ref 12]

**Assessment: Confirmed dangerous. The mechanism is additive/synergistic serotonergic activity risking serotonin syndrome. This flag in the seed brief is well-supported.**

### Cannabis — Unknown

The seed brief flags cannabis interaction as "unknown." No published interaction data between 4-AcO-DET and cannabis was identified. Cannabis can intensify the subjective effects of serotonergic psychedelics and may increase risk of anxiety and panic. THC has activity at CB₁ receptors distinct from the serotonin system. The interaction remains pharmacologically undefined for this specific compound.

### MAOIs — Class-Level Danger (Not in Brief)

Not listed in the seed brief but is a critical class-level concern: monoamine oxidase inhibitors (MAOIs) would be expected to dramatically potentiate 4-AcO-DET's effects by inhibiting the MAO-A-mediated metabolic inactivation of its active metabolite 4-HO-DET (analogous to psilocin, for which MAO-A is a key metabolic enzyme per Meshkat et al. 2025 [Ref 13]). This could lead to unpredictable, prolonged, or dangerous serotonergic effects.

**⚠️ FLAG — MAOI interaction not listed in the brief's known interactions. This is a safety-critical omission. Recommend adding as "dangerous" based on class mechanism (MAO-A metabolism of active metabolite).**

### SSRIs/SNRIs — Class-Level Interaction

SSRIs and SNRIs block SERT and may reduce or potentiate psychedelic effects. Class-level risk of serotonin syndrome exists. Not listed in brief.

**⚠️ FLAG — SSRI interaction not listed in the brief. Recommend adding.**

### Lithium — Class-Level Risk

Lithium combined with psychedelics has been associated with seizures and cardiac arrhythmias in case reports for other serotonergic psychedelics. Not listed in the brief; relevant to flag for editorial review.

---

## Legal Status

### United Kingdom
4-AcO-DET is a **Class A drug** under the Misuse of Drugs Act 1971 via the generic tryptamine catch-all clause [Ref 27 as instrument context; confirmed by web search]. The clause controls "any compound structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification," covering 4-acetoxy tryptamines as esters of Class A hydroxy tryptamines. Additionally, 4-AcO-DET is covered by the **Psychoactive Substances Act 2016** (in force from 26 May 2016), which bans supply of all psychoactive substances [Ref 27].

### United States
4-AcO-DET is **not explicitly scheduled** under the Controlled Substances Act as a standalone substance. However:
- Its parent compound **DET (N,N-diethyltryptamine) is DEA Schedule I** (code 7434) [Ref 30] and listed in Schedule I of the UN 1971 Convention on Psychotropic Substances
- Under the **Federal Analog Act (21 U.S.C. § 813)**, 4-AcO-DET could potentially be prosecuted if intended for human consumption, given its structural and pharmacological similarity to DET
- The DEA's 2022 proposed rule [Ref 29] targeted related compounds (4-OH-DiPT, DiPT, 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT) for Schedule I placement, but was withdrawn in July 2022. This indicates active DEA scrutiny of this compound class.

**⚠️ FLAG — The DEA 2022 proposed rule withdrawal does not confirm 4-AcO-DET is permanently unscheduled. The regulatory environment is actively evolving.**

### Canada
4-AcO-DET is **not explicitly listed** as a controlled substance under the Controlled Drugs and Substances Act (CDSA) as of 2025 [web-retrieved]. However, its legal status under analog provisions requires legal expertise to confirm definitively.

### Australia
Not explicitly confirmed for 4-AcO-DET in the TGA Poisons Standard [Ref 1 — web search, no specific entry found]. By analogy to psilocin esters, it may be captured as a Schedule 9 prohibited substance, but this was not verified from primary Australian legislative sources.

**⚠️ FLAG — Australia and Germany legal status could not be confirmed from primary sources for 4-AcO-DET specifically.**

### International
DET is listed under **Schedule I of the United Nations 1971 Convention on Psychotropic Substances** [Ref 30], obligating state parties to restrict it to scientific/medical use. 4-AcO-DET is not separately listed in the UN Convention.

---

## Clinical Trials

**No clinical trials registered on ClinicalTrials.gov for 4-AcO-DET or ethacetin.** ClinicalTrials.gov search returned zero results.

Clinical trials with **CZ-74 (4-HO-DET, the active metabolite)** were conducted in the 1960s by Leuner and Baer in Germany in the context of psycholytic therapy [Ref 20, Ref 25]. These were pre-registration era studies; no formal registry entries exist.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No feedback items to analyze.

---

## Gaps & Flags

The following gaps and flags require human editorial attention:

### Safety-Critical Gaps

1. **⚠️ No published human pharmacokinetic data for 4-AcO-DET.** All PK data is by analogy to psilocin (Meshkat 2025 [Ref 13]) or 4-OH tryptamines. Dose-response and time-action data in the brief cannot be verified against primary sources.

2. **⚠️ No published receptor binding data (Ki/EC₅₀) specific to 4-AcO-DET.** The closest data is for 4-AcO-DMT and 4-OH-DiPT. The Glatfelter 2023 paper [Ref 2] tested compounds with N,N-diethyl substitution but binding values were not reproduced in abstracts; full-text access was blocked.

3. **⚠️ No published LD50 or toxic dose data for any species.** The seed brief's "toxic dose is unknown" should be preserved. This is a safety-critical gap.

4. **⚠️ No published case reports of 4-AcO-DET adverse events or overdose.** Detection in clinical toxicology is unlikely given limited testing protocols (Malaca 2020 [Ref 6]).

5. **⚠️ Degradation products "C" and "D" from aged 4-AcO-DET samples (Erowid [Ref 17]) have unknown identity and toxicological profiles.**

### Interactions Gaps

6. **⚠️ MAOI interaction not listed in the brief's known interactions.** Based on class-level mechanism (MAO-A metabolism of 4-HO-DET, the active metabolite), this should be flagged as dangerous. Recommend adding.

7. **⚠️ SSRI/SNRI interaction not listed.** Recommend adding as caution-level.

8. **⚠️ Lithium interaction not listed.** Known class-level seizure risk warrants editorial flag.

### Chemical Identity Gaps

9. **⚠️ CAS number for 4-AcO-DET not found in primary sources.** The brief had this empty; it remains unconfirmed.

10. **⚠️ SMILES string not retrieved from PubChem via MCP tool** (tool returned only selected fields). The InChIKey (WYEVVQJLTXBMPM-UHFFFAOYSA-N) can be used to retrieve the full SMILES from PubChem directly.

### Legal Status Gaps

11. **⚠️ Australia legal status not confirmed from primary TGA Poisons Standard source.** Described as "likely Schedule 9 by analogy" only.

12. **⚠️ Germany/EU legal status not confirmed.** BtMG analog provisions may apply.

### Data Relying on Structural Analogy

The following sections rely primarily on analogy rather than 4-AcO-DET-specific data:
- Receptor binding affinities (Ki/EC₅₀ values) — inferred from 4-AcO-DMT and 4-OH-DiPT
- Pharmacokinetics — inferred from psilocin (Meshkat 2025 [Ref 13])
- Tolerance mechanism — inferred from DOI/LSD class data (de la Fuente Revenga 2022 [Ref 10])
- Dependence liability — inferred from DiPT/DIPT class (Gatch 2011 [Ref 9])
- Duration data — inferred from 4-HO-DET TiHKAL entries [Ref 28]